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Zusammenfassung

Mit der Entwicklung “rekombinanter” DNA-Techniken begann ein neues Zeitalter für die
Herstellung von Proteinen, sowohl im wissenschaftlichen Bereich als auch bei der industriellen
Nutzung. Allerdings ist die Reinigung der rekombinant produzierten Proteine nicht immer einfach.
In dieser Arbeit wurden drei pharmakologisch interessante Proteine exprimiert und es wurde dabei
versucht, durch neuartige Genkonstrukte Proteine zu erhalten, deren Aufarbeitung gegenüber der
bisherigen Vorgehensweise vereinfacht ist. Bei den rekombinant exprimierten Proteinen handelt es
sich um das humane Neurotrophin 3 (hNT3), das Pflanzentoxin Gelonin sowie um ein
Fusionsprotein aus Gelonin und der extrazellulären Domaine der   -Untereinheit des humanen
Acetylcholin-Rezeptors (Gelonin-AchR).
In dem ersten Projekt wurden die Gene für das Pflanzentoxin Gelonin, die extrazelluläre
Domaine der   -Untereinheit des humanen Achetylcholin-Rezeptors sowie für ein Fusionsprotein
bestehend aus beiden Komponenten cloniert und die Genprodukte in E. coli exprimiert. Das Gen
für Gelonin hatte Shi Ya-Wei chemisch synthetisiert und freundlicherweise zur Verfügung gestellt.
Es wurde zunächst in den Vektor pUC118 eincloniert und dann in pET28a transferiert und
exprimiert. Das rekombinante Gelonin konnte in zwei Schritten gereinigt werden und man erhielt
eine homogene Bande im SDS-Gel im Bereich von 28 kD. Die Expression der extrazellulären
N-terminalen Domaine der   -Untereinheit des Acetylcholin-Rezeptors (Aminosäuren 1-181)
wurde ebenfalls cloniert und in E. coli  exprimiert. Allerdings entstanden dabei unlösliche
Aggregate, die nicht oder in nur sehr geringem Maße renaturiert werden konnten. Selbst bei
Coexpression mit dem Chaperonin-System GroELS konnten nur geringe und schlecht
reproduzierbare Mengen an löslichem Produkt erhalten werden. Eine Lösung des Problems ergab
sich mit der Konstruktion eines Fusionsproteines bestehend aus Gelonin und der AchR-Domaine,
da durch die höhere Löslichkeit des Gelonins eine Solubilisierung des Fusionsproteins mit
anschließender Reinigung möglich wurde. Die biologische Aktivität des rekombinant produzierten
Gelonins sowie der Gelonin-Acetylcholin-Rezeptor-Fusion wurde im in-vitro  Translationstests
gezeigt. Die korrekte Faltung der AchR-Domaine wurde im ELISA mit Hilfe spezifischer
monoklonaler Antikörper nachgewiesen.
Die Expression und Reinigung des rekombinanten hNT3 wurde in einem Protein-Selbst-
Spleiß-System durchgeführt. Dazu wurde ein 380 bp-Fragment (entspricht einem Protein mit 14
kD) der bekannten hNT3-DNA-Sequenz mit Hilfe von PCR aus menschlichem Vollblut
amplifiziert und in den Vektor pTXB1 eincloniert. pTXB1 enthält zusätzlich ein Intein-Fragment,


an dem eine Chitin-Bindungsproteindomaine (CBD) anfusioniert ist. Ein ähnliches Konstrukt,
pJLA-hNT3, wurde zusätzlich hergestellt, bei dem die Genexpression unter einen
Hitzeschockpromotor gestellt ist. Von beiden Konstrukten konnte das Zielprotein
hNT3-intein-CBD entweder nach Induktion mit IPTG oder nach Hitzeschock erhalten werden. Das
exprimierte Protein akkumulierte in Aggregatform und wurde nach Denaturierung und
Renaturierung als lösliches Fusionsprotein auf einer Chitin-Affinitätssäule gereinigt. Nach
Spaltung in Gegenwart von DTT wurde ein 14 kD Protein erhalten, das dem hNT3 entspricht.
Sowohl das hNT3 als auch das Fusionsprotein hNT3-intein-CBD zeigten dieselbe biologische
Aktivität basierend auf Wachstumsassays an dorsalen Ganglien in Hühnerembryonen.

























Abstract

The development of recombinant DNA techniques opened a new era for protein production
both in scientific research and industrial application. However, the purification of recombinant
proteins is very often quite difficult and inefficient. Therefore, we tried to employ novel techniques
for the expression and purification of three pharmacologically interesting proteins: the plant toxin
gelonin; a fusion protein of gelonin and the extracellular domain of the    subunit of the
acetylcholine receptor (gelonin-AchR) and human neurotrophin 3 (hNT3).
Recombinant gelonin, acetylcholine receptor α subunit and their fusion product,
gelonin-AchR were constructed and expressed. The gelonin gene, a 753 bp polynucleotide was
chemically synthesized by Ya-Wei Shi et al.  and was kindly provided to us. The gene was first
inserted into the vector pUC118 yielding pUC-gel. It was subsequently transferred into pET28a
and pET-gel was expressed in E. coli. The product, gelonin was soluble and was purified in two
steps showing a homogeneous band corresponding to 28 kD on SDS-PAGE. The expression of the
extracellular domain of the   -subunit of AchR always led to insoluble aggregates and even upon
coexpression with the chaperonin GroESL, very small and hardly reproducible amounts of soluble
material were formed, only. Therefore, recombinant AchR- gelonin was cloned and expressed in
the same host. The corresponding fusion protein, gelonin–AchR, again formed aggregates and it
had to be solubilized in 6 M Gu-HCl for further purification and refolding. The final product,
however, was recognized by several monoclonal antibodies directed against the extracellular
domain of the   -subunit of AchR as well as a polyclonal serum against gelonin.
Expression and purification of recombinant hNT3 was achieved by the use of a protein
self-splicing system. Based on the reported hNT3 DNA sequence, a 380 bp fragment
corresponding to a 14 kD protein was amplified from genomal DNA of human whole blood by
PCR. The DNA fragment was cloned into the pTXB1 vector, which contains a DNA fragment of
intein and chintin binding domain (CBD). A further construct, pJLA-hNT3, is
temperature-inducible. Both constructs expressed the target protein, hNT3-intein-CBD in E. coli
by the induction with IPTG or temperature, however, as aggregates. After denaturation and
renaturation, the soluble fusion protein was slowly loaded on an affinity column of chitin beads. A
14 kD hNT3 could be isolated after cleavage with DTT either at 4˚C or 25˚C for 48 h. Based on
nerve fiber out-growth of the dorsal root ganglia of chicken embryos, both, hNT-3-intein-CBD and
hNT3 itself exhibit almost the same biological activity.
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Part I   Immunotoxins

Conjugates composed of tissue-specific monoclonal antibodies and toxins have found wide interest
as potential anti-cancer drugs. Far less common is the similar approach to use conjugates of
antigens with toxins for the treatment of autoimmune diseases. In this case, the auto-antigen would
direct the toxin to its target, antigen-specific lymphocytes, which would be selectively eliminated
resulting in an antigen-specific suppression of the immune system. This approach, as initially
suggested by Géza Filipp, was successfully taken in the laboratory of Trommer in Kaiserslautern
[1] in the case of experimental autoimmune Myasthenia gravis (EAMG). Myasthenic rats were
treated with a conjugate composed of the acetylcholine receptor (AchR) and the plant toxin
gelonin leading to a substantial recovery of functional receptors in the neuromuscular endplates of
these animals. Neither the receptor nor the toxin alone had comparable effects. However, the
antibody titer against the receptor raised during treatment. A possible reason could have been
immune reactions against pathophysiologically irrelevant parts of the receptor from Torpedo which
had been used in the conjugates [1]. Hence, in the current work, recombinant fragments of the
 
-subunit, which contains the main immunogenic region (MIR) will be employed.

1A   Gene clone, expression and characteristics  of gelonin

1A.1   Ribosome inactivating proteins

Ribosome inactivating proteins (RIPs) are bio-macromolecules that specifically interfere with
eukaryotic protein translation. Most plant and bacterial RIPs exert their effects through
catalytically and irreversibly inactivating the 60S subunit of eukaryotic ribosomes [2]. Plant RIPs
can be categorized into two groups: type-I RIPs, most of them being glycoproteins such as gelonin,
bryodin or trichosanthin, are single-chain proteins with molecular weight of about 30 kD. However,
type-II RIPs, such as ricin or abrin, consist of two polypeptide chains (A and B) which are linked
by a disulfide bridge. The enzymatic property of type-II RIPs is associated with the A chain, while
the B chain is like a lectin, which facilitates entry of the toxin into intact cells by binding
non-specifically to galactose moieties on the cell surface [3, 4, 5].
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1A.1.1   Toxicity

The potent cytotoxicity of heterodimeric ricin was first described over a century ago. The
mechanism by which RIPs inactivate 60S ribosomal subunits was elucidated by Endo and his
colleagues in 1987 [1, 6]. The mechanism was first deduced from ricin A chain, but has not been
shown to operate for all plant RIPs and for bacterial toxins such as Shigella  toxin and the
Shiga-like toxins from certain enteropathogenic strains of E. coli. Ricin A chain is an RNA specific
N-glycosidase that hydrolytically cleaves a single N-glycosidic bond from among over four
thousand nucleoside bases present in 28S rRNA (4800 bases). A specific adenine residue is
removed (A-4324 in the case of rat liver 28S rRNA) resulting in the inability of the ribosome to
bind elogation factor 2 and thus terminating the elongation cycle of protein synthesis. Several
rRNA sequences surrounding the adenine residue removed by plant RIPs are shown in Table 1A.1.
The ricin A chain can specifically depurinate 1500-2000 rat liver ribosomes per minute. The
preferred substrate for ricin A chain is 26/28S rRNA in native 60S ribosomal subunits. Whilst the
naked 26/28S rRNA can also act as a substrate but the Kcat  for the latter reaction is approximately
105- fold lower than that for the former. This suggests that the native secondary structure of
ribosome-associated 26/28S RNA is important for the action of RIPs and that ribosomal proteins
may play an important role in maintaining this RNA conformation, and/or in providing a high
affinity binding site for the toxin [7].

Table 1A.1   Nucleotide sequence in rRNA surrounding the adenine* 
    removed by RNA N-glycosidase [4]

Ribosome sources Sequences
Xenopus
Rat
Yeast
Wheat
E.coli
5’….AGUACGA*GAGGAAC….3’
5’….AGUACGA*GAGGAAC….3’
5’….AGUACGA*GAGGAAC….3’
5’….AGUACGA*GAGGAAC….3’
5’….AGUACGA*GAGGACC….3’
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Table 1A.2   Some examples of single-chain RIPs [4]















Single chain RIPs (Table 1A.2) are potent inhibitors in cell-free translation systems, they exhibit
the low toxicity to intact cells; IC50 value for protein synthesis inhibition by whole cells being 105
to 107  fold higher than those for ribosomes. In contrast to double chain RIPs (dsRIPs), single chain
RIPs (scRIPs) [8] cannot normally enter into cells and cannot therefore readily reach their
ribosomal sites. However, the cytotoxity of single chain RIPs can be dramatically enhanced if
entry into the cell cytoplasm is facilitated. This can be achieved by conjugating RIPs to antibodies
[9], or by incorporating RIPs into some structures such as liposomes or erythrocyte ghosts which
can be fused with intact cells.

The most thoroughly studied toxic proteins from plants are the cytotoxic lectins such as ricin and
abrin (Table 1A.3). These all are N-glycosylated heterodimers consisting of two polypeptides
linked together by a single disulfide bond. The A chain is a RNA-specific N-glycosidase,
structurally and functionally corresponding to the single chain RIPs. Cytotoxity is conferred by the
B chain, which allows the holotoxin to bind to the cell surface and which ultimately leads to the
penetration of the toxic A chain into the cell cytosol.



Plant sources Inhibitor Mr (dalton) Glycosylated
Phytolacca Americana
(pokeweed) seeds or leaves
Pokeweed antiviral
Proteins (PAP)
30,000 No
Triticum aestivum
(wheat) seeds
Tritin 30,000 No
Gelonium multiflorum
seeds
Gelonin 30,000 Yes
Momordica charantia
(bitter ground) seeds
Momordin 31,000 Yes
Saponaria officinalis
(soapwort) seeds
Saporin 29,500 No
Dianthus carophyllus
(carnation) leaves
Dianthin 30,000 Yes
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Table 1A.3   Cytotoxic heterodimeric lectins [4]

Plant sources Inhibitors Mr (dalton) Glycosylated
Ricinus communis
(castor bean) seeds
Ricin
A chain
B chain
65,000
32,000
34,000
Yes
Yes
Yes
Abrus precatorius
(jequirity bean) seeds
Abrin
A chain
B chain
65,000
30,000
36,000
Yes
No
Yes
Adenia digitata
roots
Modeccin
A chain
B chain
63,000
28,000
31,000
Yes

Adenia volkensii
roots
Volkensin
A chain
B chain
62,000
29,000
36,000
Yes
Viscum album
(mistletoe) leaves
Viscumin
A chain
B chain
60,000
29,000
32,000
Yes

The binding of cytotoxic lectins to the surface of target cells is opportunistic and is achieved by
reversible interactions between the B chain and any carbohydrate moiety containing terminal
galactose residues. Such residues occur on both glycoproteins and glycolipids and the abundance
of such potential binding sites on most mammalian cells ensures a high concentration of bound
toxin at the cell surface. Hela cells for example, possess 3×107  binding sites per cell for ricin [10].

1A.1.2   Membrane translocation

At some stages during the entry process, ricin A chain crosses an intracellular membrane into the
cytosol, although the actual site at which this translocation step occurs has not been convincingly
established. Translocation of a toxic fragment into the cytosol is best understood for diphtheria
toxin. This bacterial toxin enters the cytosol from acidified endosomes where the low pH induces a
conformational change in the B fragment. This change results in the exposure of B chain
hydrophobic domains which insert into the endosomal membrane and somehow facilitate transfer
of the A fragment into the cytosol. Because of this requirement for low pH for translocation, cells
in which endosomal and lysosomal pH has been increased (by treatment with NH4Cl, for example),
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or mutant cell lines defective in the acidification of endosomes, are resistant to diphtheria  toxin.
Although the endosome has also been implicated as the intracellular site of ricin translocation, it
appears that the endocytosis of ricin continues beyond the endosomal stage before translocation
takes place. Treatments which increase endosomal pH do not reduce ricin toxicity, and the lag time
between cellular exposure to ricin and measurable decrease in protein synthetic activity (60-90 min)
is considerably longer than that for the bacterial toxin. Several studies using immunoelectron
microscopy have shown that endocytosed ricin is first delivered to the endosomes and a fraction
subsequently appears within the Golgi complex, in particular the trans-Golgi network [11]. There
is now considerable experimental evidence that ricin must reach the Golgi complex in order to
exert its cytotoxic effects. A number of treatments that induce morphological changes as the
disruption of the Golgi by brefeldin A, inhibit the cytotoxicity of ricin and pseudomonas  exotoxin
A, while having no effect on the cytotoxicity of diphtheria toxin [12].

Ricin B chain is required for the efficient translocation of ricin A chain into the cytosol, beyond its
role in the initial cell surface binding of the holotoxin [13]. This B chain requirement is not
absolute however, since many immunotoxins containing ricin A chain alone are potently cytotoxic.
Clearly the A chain can cross a membrane in the absence of B chain, which argues against the B
chain having a direct function in the translocation step. It is possible that the B chain facilitates
translocation indirectly by delivering the A chain to a translocationally-competent compartment. If
this is the case, the association with the B chain might effectively prevent the A chain from
inserting into membranes until such a compartment has been reached. The intracellular role of ricin
B chain envisaged above could result from the B chain binding to intracellular
galactose-containing components (receptor), particularly in the trans-Golgi. Such galactose binding
could reduce the amount of ricin recycled back to the cell surface, it might allow ricin to move
from the Golgi to the ER as discussed above, or it could have a more direct role in membrane
translocation within the Golgi complex. In these situations, the galactose binding sites are clearly
important for the B chain’s intracellular role in cellular intoxication [14, 15].

1A.1.3   Antiviral activity

The first single chain RIP to be isolated and studied was pokeweed antiviral protein (PAP). It was
known that leaf extracts from several plants, including Phytolacca americana (pokeweed), when
mixed with a suspension of tobacco mosaic virus, prevent the mechanical transmission of viral
infection to other plants. The pokeweed antiviral factor was purified and identified as a single
chain RIP. PAP also prevented animal virus replication in mammalian cells, where it was found to
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inhibit protein synthesis by virally infected cells at PAP concentrations which did not affect normal
cells. All RIPs are known to be more toxic to virus-infected cells than to non-infected cells,
apparently because infection permeabilizes the host and allows the toxins to penetrate into the
cytosol [16].

From early studies on the antiviral activity of plant extracts it was concluded that while these
extracts prevented viral infection in other plant species, they did not prevent infection of the very
plants from which they derived. This suggested that the antiviral principle did not act directly on
the virus but that its effectiveness was due to some action on the infected plant. Now, it has been
clearly shown that pokeweed ribosomes are sensitive to PAP [17]. A study of the intracellular
location of PAP has shown that this RIP is heavily sequestered in the cell wall of pokeweed cells
[18], a location consistent with its proposed anti-viral role. Thus viral infection of pokeweed cells
might provoke a damage limitation exercise in which the infected cells become permeable to their
own extra-cellular RIP that enters the cytosol and depurinates the pokeweed ribosomes and thereby
prevents viral replication.

1A.1.4   Ribosome specificities

The active site was identified by x-ray analysis of the ricin A chain and confirmed by site-directed
mutagenesis. This region is highly conserved in RIPs (Table 1A.4). Their ribosomal substrate
specificities however, can be very different, for example, mammalian and yeast ribosomes are very
sensitive to ricin A chain, plant ribosomes much less so, and prokaryotic ribosomes are completely
insensitive. In spite of the fact that the consensus sequence around the target adenine is also highly
conserved in all 23, 26, 28S rRNAs, the sensitivity of a single type of ribosome to different RIPs
also varies markedly, for example, wheat germ ribosomes are relatively insensitive to ricin A chain
but are 1000 to 10,000 times more sensitive to the single chain RIP dianthin.

The most dramatic variation in sensitivity which has emerged recently is that E. coli ribosomes
were believed to be completely insensitive to all RIPs. Indeed, E. coli has been successfully used
as host to produce recombinant ricin A chain and abrin A chain [19]. These proteins were produced
cytoplasmically where they accounted for up to 10% of the total bacterial protein without affecting
bacterial growth. Mirabilis  antiviral protein (MAP) cytoplasmically in E. coli resulted in severely
inhibited growth of the host, caused by the recombinant product, and the yield of product was very
low. Subsequently MAP was shown to inhibit protein synthesis by E. coli ribosomes in  vitro, in
contrast to the effect of the ricin or abrin A chain [20]. More recently it was shown that both PAP
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and dianthin likewise inhibit protein synthesis by E. coli ribosomes. These single chain RIPs are
able to specifically depurinate E. coli 23S rRNA at the expected site (Table 1A.1). The adenine
residue -glycosidically removed from 23S rRNA by the RIPs is known to be a key binding residue
for EF-G and EF-Tu [21].

Table 1A.4   Comparison of active site region of plant toxins [4]

RIP Residue position Amino acid sequence
Ricin A chain 172-185 CIQMISEA*ARFQYI
Abrin A chain 158-171 IIQMVSEA*ARFRYI
PAP 170-183 AIQMVSEA*ARFKYI
MAP 163-176 AIQMVSEA*ARFKYI
Saporin 171-184 AIQMTAEA*ARFRYI
Diarithin 152-165 AIQMTAEA*ARFRYI

1A.1.5   Gelonin

Gelonin extracted from seeds of the plant Gelonium multiflorum belongs to type-I ribosome
inactivating proteins. Gelonin is glycosylated with terminal mannose residues. Due to lack of the
B-chain domain binding the cell surface, it normally does not enter intact cells. Even if it enters
cells via a different mechanism, e.g. as a conjugate, it exhibits a different intracellular distribution,
compared with type-II RIPs. Gelonin is assumed to be trapped in the endosomal/lysosomal
compartment, a location explaining its relatively low toxicity. In cell-free systems, however,
gelonin has the powerful N-glycosidase activity on eukaryotic ribosomes by releasing
adenine-4324 from a vital region of the 28S rRNA unit [20].

Table 1A.5   The amino acid sequence of gelonin precursor

10 20 30 40 50
MKGNMKVYWI KIAVATWFCC T T I V LG S TA R I F S LP TNDEE ETSKTLGLDT
60 70 80 90 100
VSFSTKGATY ITYVNFLNEL RVKLKPEGNS HGIPLLRKKC DDPGKCFVLV
110 120 130 140 150
ALSNDNGQLA EIAIDVTSVY VVGYQVRNRS YFFKDAPDAA YEGLFKNTIK
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160 170 180 190 200
TRLHFGGSYP SLEGEKAYRE T T D LG I E P L R IG IKKLDENA IDNYKPTE IA
210 220 230 240 250
SSLLVVIQMV SEAARFTFIE NQIRNNFQQR I R PANN T I S L ENKWGKLSFQ
260 270 280 290 300
IRTSGANGMF SEAVELERAN GKKYYVTAVD QVKPKIALLK FVDKDPKTSL
310 316  
AAELI IQNYE S L V G F D  
*This sequence is from Swiss-prot P33186. The residue G from 47 is the N-terminus of recombinant gelonin
and K at the stop of 297 is the C-terminus.

1A.1.5.1   The primary structure

Gelonin consists of 251 amino acid residues, similar to other scRIPs such as monorcharin (247 aa)
and the A-chain of dsRIPs for instance ricin A-chain (267 aa). Though the conserved amino acid
residues among them are less than 40%, their structure is the same from the results of different
RIPs cross-reaction with specific antiserum. In vivo, an inactive precursor of gelonin is first
biosynthesized and then transported to safe compartments within the cell. Finally, the functional
gelonin is produced by glycosylation with the post-translational modification. The primary
structure of the precursor is as shown above Table 1A.5 [21].

1A.1.5.2   The conformation

Hosur et al. published a three-dimensional structure of gelonin at 1.8 Å resolution [22], which is
basically identical to the conformation of ricin A and   -momorcharin (Fig 1A.1).







           Fig 1A.1  Superposition of gelonin, ricin A and   -momorcharin [22]
The stereoview shows C

tracing: bold, gelonin; Mediun, ricin A; light, α-momorcharin. Every 10th   residue of
gelonin is marked. Differences are mostly in the loop regions.
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As shown in Fig 1A.1, structurally, gelonin belongs to the (  +  ) class of proteins. With respect to
the
 
 strands,
 
1,
 
4,
 
5,
 
6,
 
7 and
 
8 form a mixed
 
 sheet, and
 
2,
 
3  as well as
 
9,
 
10  form two
antiparallel beta ribbons, while the helix regions, except for short segments of type 310  (123 to 125
and 237 to 239) are all of the   -helix type. Thus, there are two distinct structural domains in the
gelonin molecule, one large and a small one. The former consists of residues 3-32 and 40-187
while the latter is composed of residues 33-39 and 188-247.

1A.1.5.3   Catalytic mechanism

Active site   From the varies studies as X-ray diffraction, site-directed mutagenesis and chemical
modification etc, the active site residues of gelonin are Tyr74, Arg169, Gly111, Glu166, Tyr113
and Trp198. There is a number of hydrogen bonding interactions between these residues, such as
Arg169/Glu166. In addition, the water molecules also participate in the catalytic reaction, there are
at least two hydrogen bonds from water to protein atoms.

Glycosylation   Gelonin is a glycoprotein with terminal mannose residues. It is known that
Asn82 and Asn189 are two potential glycosylation sites in the N-terminal glycosylation of gelonin.

Catalytic mechanism   As a glycosidase, it is the cleavage of the N-glycosidic bond of a specific
adenine in 28S rRNA from the 60S subunit of eukaryotic ribosomes. It has been shown that the
true substrate is a ribo-oligonuclotide hairpin in which the double helical stem is at least three base
pairs long and the connecting hairpin loop contains the sequence GAGA. The first adenine will be
removed by RIPs. The removal of adenine is a hydrolysis reaction and involves addition of a water
molecule to the substrate. Based on the structure, two kinds of molecular catalytic mechanisms
have been suggested. Both include an oxycarbonium ion intermediate which is generated by
different chemical steps. However, in both methods a water molecular is required for nucleophilic
attack on the C1’ atom of the intermediate [23].

1A.1.6   Research goals

Toxins as generally utilized in immunoconjugates belong to a group of enzymes that inhibit the
protein biosynthesis [24]. Gelonin, a plant toxin from Gelonium multiflorum has successfully been
employed in such approaches including its application in antigen-specific immune suppression [1].
However, it is not easily available from natural sources. Recombinant gelonin has been reported
[21] but the clone is not available from the authors. In their work the cDNA was obtained from
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highly fragmented mRNA isolated from the seeds of Gelonium multiflorum. Based on the
published sequence of gelonin, Ya-Wei Shi et al. synthesized the gene chemically in four
fragments which were kindly provided to us [25]. In these constructs some of the bases had been
substituted for the corresponding nucleotides in the published DNA sequence in order to yield
optimized codons for the same amino acids in E. coli.  These DNA fragments will now be fused
and used for the expression of gelonin.

1A.2   Results and discussion

1A.2.1   Gene clone of gelonin

The gene coding for gelonin was kindly provided by Ya-Wei Shi et al. in 4 consecutive fragments
as shown in Fig 1A.2. Ya-Wei Shi et al. also provided the two recombinant plasmids pUC-gel I and
pUC-gel II containing gelonin fragments 1+2 and 3+4 respectively [25].

A.  DNA-
B   DNA- ATG    
GGCCTGGAC
GGCCTGGAT
ACCGTGAGCT
ACCGTGAGCT
TTAGCACTAA
TCAGCACCAA
AGGTGCCACT
AGGCGCCACC
 Fragment 1  
TATATTACCT
TATATTACCT
ACGTGAATTT
ATGTGAACTT
CTTGAATGAG
CCTGAACGAA
CTACGAGTTA
CTGCGTGTGA 
AATTGAAACC
AACTGAAACC
   
CGAAGGTAAC
GGAAGGCAAC
AGCCATGGAA
AGCCATGGCA
TCCCATTGCT
TTCCGCTGCT
GCGCAAAAAA
GCGTAAAAAA
TGTGATGATC
TGCGATGATC
   
CTGGAAAGTG
CGGGCAAATG
TTTCGTTTTG
CTTCGTGCTG
GTAGCGCTTT
GTGGCGCTGA
CAAATGACAA
GCAACGATAA
TGGACAGTTG
CGGCCAGCTA
    Fragment 2
GCGGAAATAG
GCGGAAATTG
CTATAGATGT
CGATTGATGT
TACAAGTGTT
GACCAGCGTG
TATGTGGTGG
TATGTGGTGG
GCTATCAAGT
GCTATCAGGT
   
AAGAAACAGA
GCGTAACCGT
TCTTACTTCT
AGCTATTTCT
TTAAAGATGC
TCAAAGATGC
TCCAGATGCT
GCCGGATGCG
GCTTACGAAG
GCGTATGAAG
   
GCCTCTTCAA
GCCTGTTCAA
AAACACAATT
AAACACCATT
AAAACAAGAC
AAAACCCGTC
TTCATTTTGG
TGCATTTTCGG
CGGCAGCTAT
CGGCAGCTAT
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CCCTCGCTGG
CCGAGTCTAG
AAGGTGAGAA
AAGGCGAAAA
GGCATATAGA
AGCGTATCGT
GAGACAACAG
GAAACCACCG
ACTTGGGCAT
ATCTGGGCAT
Fragment 3   
TGAACCATTA
TGAACCGCTG
AGGATTGGCA
CGTATTGGCA
TCAAGAAACT
TTAAAAAACT
TGATGAAAAT
GGATGAAAAC
GCGATAGACA
GCGATTGATA
   
ATTATAAACC
ACTATAAACC
AACGGAGATA
GACCGAAATT
GCTAGTTCTC
CCGAGCAGCC
TATTGGTTGT
TGCTGGTGGT
TATTCAAATG
GATTCAGATG
   
GTGTCTGAAG
GTGAGCGAAG
CAGCTCGATT
CGGCGCGTTT
CACCTTTATT
CACCTTCATT
GAGAACCAAA
GAAAACCAGA
TTAGAAATAA
TTCGTAACAA
   
CTTTCAACAG
CTTCCAGCAG
AGAATTCGCC
CGGATCCGTC
CGGCGAATAA
CGGCGAACAA
TACAATCAGC
CACCATTAGC
CTTGAGAATA
CTGGAAAACA
 Fragment 4  
AATGGGGTAA
AATGGGGCAA
ACTCTCGTTC
ACTGAGCTTC
CAGATCCGGA
CAGATTCGTA
CATCAGGTGC
CCAGCGGCGC
AAATGGAATG
GAACGGCATG
   
TTTTCGGAGG
TTCAGCGAAG
CAGTTGAATT
CGGTGGAACT
GGAACGTGCA
GGAACGTGCG
AATGGCAAAA
AACGGCAAAA
AATACTATGT
AATATTATGT
   
CACCGCAGTT
GACCGCGGTG
GATCAAGTAA
GATCAGGTGA
AACCCAAAAT
AACCGAAAAT
AGCACTCTTG
TGCGCTGCTG
AAGTTCGTCG
AAATTCGTCG
   
ATAAAGATCC
ACAAAGATCC
TAAATAATAAG
GAAATAATAAG
 

Fig 1A.2   A comparison of DNA sequence between native gelonin gene and synthetic
gelonin gene  A. Original DNA sequence; B. Synthetic DNA sequence showing the fragments 1-4 provided
by Ya-Wei Shi et al [25].
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1A.2.1.1   Construction of pUC-gel

Two recombinant plasmids harboring parts of the gelonin gene, pUC-gel I with the fragments of
gelonin 1 and 2 and pUC-gel II with the fragments of gelonin 3 and 4 were provided by Ya-Wei
Shi [25]. Based on the restriction enzyme sites (Fig 1A.3), pUC-gel I and pUC-gel II were
separately digested with XbaI and EcoRI at 37°C for 2 h, and then separated by an 1% LM agarose
gel electrophoresis, at 80 V, 1.5 h. The large fragment cut from pUC-gel I and the small fragment
from pUC-gel II were collected and spun at 13,000 r/m for 30 sec and incubated at 70°C for 10
min and transferred into 42°C incubator for 5 min. Finally, 1 µl 10x β- agarase buffer and 1µl
β-agarase were added and the mixture was incubated for 1 h at 42°C before ligation.
                              192    382    572
AccI        -------- | -------- | -------- | ------|-       GT’CGAC
BamHI      -------- | -------- | ------- | | --------       G’GATCC
BsmI        ----|--- | -------- | -------- | --------       G’CATTC
Ecl136       --------| -------- | -------- | ---|----       GAG’CTC
EcoRI       -------- | -------- | -------- | -------|       G’AATTC
HincII       -------- | -------- | -------- | ------|-       GTC’GAC
NcoI        ----| --- | -------- | -------- | --------       C’CATGG
NheI        ------- | | -------- | -------- | --------       G’CTAGC
SacI         --------| -------- | -------- | ---|----       GAGCT’C
SacII        -------- | -------- | -------- | -----|--       CCGC’GG
SalI         -------- | -------- | -------- | ------|-       G’TCGAC
StuI         -------- | ----|--- | -------- | --------       AGG’CCT
StyI         ----|--- | -------- | -------- | --------       C’CATGG
XbaI        -------- | ------ |- | -------- | --------       T’CTAGA

Fig 1A.3   The relative location of the restriction enzyme sites of synthetic gene

1A.2.1.2   Extraction and identification of pUC-gel

After ligation and transformation, a single colony was picked and transferred into 5 ml
LB+ampicillin at 37°C and shaking overnight. The plasmids were extracted using the plasmid-mini
kit, then digested with XbaI and EcoRI. It was shown from the digestion of the pUC-gel with
XbaI/EcoRI on a 1.2% agarose gel that a band corresponding to about 415 bp had formed, which is
akin to Gel 3+4 (415 bp) (See lane1 in Fig 1A.4). This indicates that the Gel 3+4 fragment had
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been inserted into the vector and the whole gene of gelonin was present (Fig 1A.4). The new
recombinant plasmid pUC-gel was constructed, which contains the whole gene of gelonin
(Fig 1A.5)














1A.2.2   Construction of an expression plasmid

For the expression of the recombinant gelonin, plasmid pET28a containing the T7 promoter,
kanamycin (Kan) resistance and IPTG induction was chosen as vector. According to MCS of the
vector, both pUC-gel and pET28a were digested with NdeI and EcoRI respectively, the gene
fragment of gelonin from pUC-gel was then inserted into pET28a to construct a recombinant
pET-gel (Fig 1A.5). By the analysis of transformation,  plasmid extraction, double enzymatic
digestion and DNA sequence assay, it was further confirmed that the vector pET-gel contained a
753 bp DNA fragment, which was the same as that designed in Fig 1A.2.









Fig 1A.4   Identification of pUC-gel
Mr. DNA marker
Lane1: pUC-gel cleavaged with XbaI/EcoRI
(Gelonin gene should be about 760 bp)
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Fig 1A.5   Construction of the expression vector containing the gelonin gene
      (pUC-gel I, pUC-gel II were provided by Ya-Wei, Shi [25])


1A.2.2.1   Identification of pET-gel gene

Some single colonies were transferred into 5 ml LB + ampicillin at 37°C in a shaker to reach an
optical density OD600 of 0.7-0.8. Isopropyl-1-thio-β-D–galactopyranoside (IPTG) was added to a
final concentration of 1 mM for induction and the culture was allowed to grow for another 3 h.
Then 40   l broth mixed with 3x sample buffer 10   l was boiled for 5 min before loading on 12%
SDS-PAGE. The expression product should show a band around 28 kD if the recombinant plasmid
was correct. It is shown in Fig 1A.6 that strains of 3# (Lane 3 in Fig 1A.6) and 9# (Lane 9 in Fig
1A.6) yielded a new band. It was reasoned that gelonin could be expressed in E. coli
BL21/pET-gel.
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Fig 1A.6   Electrophoretic patterns of single colony culture on SDS-PAGE
Lane1-Lane10 are the different colonies of transformed strains after ligation
on LB media plates. (Directly after ligation, the cells of BL21 were transformed with the
plasmid pET-gel and plated on LB media plates. Different colonies were picked out and
expressed in 5 ml LB culture. According to SDS-PAGE analysis, Lane3 and Lane9 show
positive clones.)

Plasmids in 3# (Lane and 9# strains were extracted and digested with NdeI and EcoRI, a band of
about 760 bp was detected on 1% agarose gel. After DNA sequence analysis, the gelonin gene was
further confirmed (Fig 1A.7).








   

Fig 1A.7   Identification of pET-gel by endonuclease digestion
         Mr: λDNA / EcoRI 4771; Lane1: pET-gel (6000 bp);
    Lane2: pET-gel digested with NdeI /EcoRI (Gelonin gene should be about 760 bp)


28 kD
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1A.2.3   Expression of pET-gel in E. coli  BL21

40   l culture of strain E. coli BL21/pET-gel stored at –80˚C was taken into 20 ml LB+16   l
kanamycin (100 mg/ml) medium in shaker, 220 r/m, 37˚C overnight, then used to inoculate
1000 ml LB+800   l kanamycin (100 mg/ml) medium. The broth was cultured to reach an
optical density (OD600nm) of approximately 0.6~0.7 and immediately induced by IPTG (final
conc. 1 mM) for another 4 h growing at the same temperature. Finally, the pellets were
harvested by centrifugation (6,000 r/m, 10 min), washed twice with 0.02 M Tris-HCl, pH7.6.
The pellets were re-suspended in 50 ml, 50 mM phosphate buffer (pH6.5) including 2 mM
DTT, 1.5 mM PMSF, 2 mM EDTA. It was sonicated 15 times on ice for 8 sec each. The
quantity of crude protein was measured by the coomassie brilliant blue assay. Usually, about
130 mg total protein from 1 L culture can be obtained.

In order to confirm whether inclusion-bodies were formed, the precipitate was dissolved in 8 M
urea, the supernatant and precipitate were subjected to 12% SDS-PAGE respectively. As shown in
Fig 1A.8, there was only a very weak band in the precipitate at 28 kD (see lane 2 in Fig 1A.8) as
compared to the corresponding band from the supernatant (Lane 3). Consequently, recombinant
gelonin is rather soluble (Fig 1A.8).

                   1   2   3   4  Mr (kD)

Fig 1A.8   Electrophoretic patterns of E. coli BL21/pET-gel culture on 12% SDS-PAGE
Lane1: Culture of E.coli BL21/pET-gel uninduction
Lane2: Precipitation after sonication and centrifugation with induction
Lane3: Supernatant after sonication and centrifugation with induction
Lane4: Culture of E.coli BL21/pET-gel with induction
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To investigate the optimal conditions for induction, we attempted to express recombinant gelonin
at different temperatures and times, i.e. 37°C for 4 h, 30°C for 4 h, or 12 °C, overnight. The
comparative results were listed in Table 1A.6. In this work, the strain BL21/pET-gel was induced
at 37°C for 4 h.

Table 1A.6   The different conditions of induction (100 ml LB medium)

Induced Temperature/time 37°C/4 h 30°C/4 h 30°C/1 h,
12°C/ overnight
Mixture (after sonication) 15 mg 13 mg 13.6 mg
Supernatant 12 mg 11 mg 11.3 mg
pellets 3 mg 2 mg 2.3 mg

1A.2.4   Purification of recombinant gelonin

To compare the different separation conditions, some matrices including Heparin 6ff,
SP-Sepharose ff, Q-Sepharose ff, Superdex 75 were tried. Finally, after SDS-PAGE analysis
the following process was chosen.

Crude proteins  SP-Sepharose ff  Dialysis  Ultra-filtration  SP-Sepharose (1ml
pre-packed column on AKTA purifier, Pharmacia)

The supernatant from sonication and centrifugation was loaded on SP-Sepharose ff, and after
washing, a stepwise elution with different concentrations of NaCl (0.2 M, 0.5 M, 1 M, in 50
mM PBS, pH6.5) was performed (Fig 1A.9). The fractions pooled in the different peaks were
examined on 12% SDS-PAGE. Gelonin could be eluted in peak 3 with 0.5 M NaCl (see lane 3
in Fig 1A.10).
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Fig 1A.10   Electrophoretic patterns of each peak pooled from SP-Sepharose ff
LaneU: pET-gel/BL21 uninduced; Lane1: pET-gel/BL21 induced
Lane2: Peak 2; Lane3: Peak 3; Lane4: Peak 4.

In order to purify the protein further, the fraction of peak 3 was first dialyzed against 50 mM
Tris-HCl, pH10.5 and then concentrated by Amicon PM10 to 7.5 mg/ml. The concentrated
sample was loaded on pre-packed SP-Sepharose (1 ml on AKTA purifier) and eluted with a
continuous gradient of 0~1 M NaCl in a buffer of 50 mM Tris-Cl, pH10.5. The fractions
pooled from different peaks were examined on 12% SDS-PAGE, which showed that pure gelonin
had been obtained (See lane 1 in Fig 1A.12).
Fig 1A.9  A preliminary elution pattern on SP-Sepharose
Sample: 20 mg proteins were applied to a SP-Sepharose the column (2.2 x 6 cm) equilibrated with 50
mM PBS, pH6.5; Flow rate: 1ml/min; Elution with stepwise of 0.2 M NaCl, 0.5 M NaCl, 1 M NaCl.
Peak 1: Flow through fraction; Peak 2: Fraction with 0.2 M NaCl; Peak 3: Fraction with 0.5 M NaCl;
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Fig 1A.11   Purification of gelonin on AKTA Purifier
                            Loading sample: 1.5 mg; Support: Pre-packed SP-Sepharose ff (1 ml).
                            Equilibration  buffer: 50 mM Tris-HCl, pH10.5.
                            Gradient: 0-1 M NaCl in 50 mM Tris-HCl, pH10.5.
                            Flow rate: 1 ml/min; Fraction size: 1 ml.
                                     











Fig 1A.12   Electrophoretic patterns of gelonin on 12% SDS-PAGE
Lane1: 5# tube from pre-packed SP-Sepharose ff (Fig 1A.11)
Lane2: 0.5 M NaCl fraction from SP-Sepharose ff
Lane3: pET-gel/BL21 induced
Lane4: pET-gel/BL21 uninduced


28 kD
5#
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1A.2.5   ELISA and Western blots

The purified sample was first investigated by ELISA and Western blots (Fig 1A.13). The mouse
anti-gelonin polyclonal antiserum was used as first antibody and peroxidase-conjugated sheep
anti-mouse Ig was the second antibody with p-nitrophenyl phosphate as substrate. For the ELISA,
wells of microtiter plates were coated with 2   g sample. The sample of the purified gelonin was
diluted to 2   g with 100   l coating buffer. The coated plates were incubated at 4 overnight.
After washing, the bound protein was incubated with the first antibody (diluted to 1:1000) and the
second antibody (diluted to 1:4000) as described in 3.5.2. The color developed in 30 min or so
was measured at 405 nm (Table 1A.7).

Table 1A.7   ELISA assay

Sample Gelonin
(recombinant)
Gelonin
(native)a
BSAb
OD405nm 0.190.01 0.170.01 0.010.01
a. Positive control (Gelonin from seeds); b. Negative control.












Fig 1A.13   Western blots analysis of gelonin
Left: SDS-PAGE; Right: Western Blots.
Mr.: Standard protein (30 kD gelonin isolated from seeds)
Lane1: Recombinant gelonin
(The first antibody is mouse anti-gelonin polyclonal antiserum)
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1A.2.6   Reticulocyte lysate activity

The biological activity of both native gelonin and recombinant gelonin was assayed in a cell free
rabbit reticulocyte lysate protein translation system, and was quantified by the incorporation of
14C-valine in vitro. Native gelonin inhibited translation by 50% at a concentration of 15 ng/ml and
recombinant gelonin at a concentration of 35 ng/ml (Fig 1A.14).











Fig 1A.14   Comparison of inhibition activity of native and recombinant gelonin.
    The amount of 14C valine incorporation was measured in relation to the concentration of
recombinant gelonin and compared to native gelonin in vitro  translation assay
(C: concentration of the sample; cpm: count/min of radioactivity)
(IC50: 50% incorporation; IC100: 100% incorporation)

1A.3   Summary

A recombinant plasmid containing the gelonin gene was constructed by molecular cloning. It was
been confirmed that the DNA sequence of gelonin in the recombinant was identical to the known
sequence by both double endonuclease cleavage and DNA sequence determination.

Engineering strain E. coli BL21/pET-gel can express gelonin, a 28 kD protein in LB+kanamycin
medium upon induction by IPTG. The expression product of recombinant gelonin is quite soluble
according to SDS-PAGE analysis so that it could be conveniently purified in the downstream
process.
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Comparing the various separation matrices and the different conditions, we decided to choose
SP-Sepharose ff as its separating matrix. It was shown from SDS-PAGE analysis that the
purification process of gelonin we employed is of high efficiency.

Finally, a preliminary toxicity test suggested from the results of Western blot analysis, ELISA and
inhibition of protein synthesis in vitro, that the bioactivity of recombinant gelonin is about the
same as that of gelonin from native sources.
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1B    Co-expression of the extracellular human acetylcholine receptor
 subunit fragment and the chaperonin GroESL in E. coli


1B.1   Introduction

Nicotinic acetylcholine receptors (AchRs) are a family of transmembrane glycoproteins including
both the muscle-type and neuronal-type AchR [1]. AchRs are known to be a part of the superfamily
of neurotransmitter-gated ion channels, each composed of five homologous subunits organized
around a central ion channel. cDNAs for 16 types of AchR subunits have been cloned from several
species [2, 3]. These include    subunits numbered 1-9,    subunits numbered 1-4,   ,  ,   subunits.
The AchR family contains three branches, one occurs in muscle and the other two are neuronal
(Fig 1B.1).
















Fig 1B.1   The structure characteristics of AchRs [3]
Numbers: the amino acid residues, Greek symbols: the subunits of AchR
Loop: disulfide site, M1-M4: transmembrane domain, Branches: glycosylation sites
Fig 1B.1 depicts the structures of the subunits comprising these three branches of the AchR family
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. The N-terminal extracellular domain consists of about 220 amino acids and contains
two homologus disulfide-linked loops. In most AchR subunits there is an N-glycosylation site at
141, some contain additional glycosylation sites in the large extracellular domain, and all contain
at least one such site  	 
 .

1B.1.1   Muscle AchRs

In 1973, the first purification of milligram amounts of acetylcholine receptor from electrophorus
electric organ resulted in the discovery of EAMG (experimental autoimmune Myasthenia gravis)
when it was found that rabbits immunized with that AchR became weak and died [10]. At that time,
muscle AchRs were well characterized electrophysiologically as Ach-gated cation channels, and
snake venom toxins such as   -bungarotoxin were just coming into use for localizing, quantifying,
and affinity purifying AchRs.

The structure of muscle-type AchRs found in the Torpedo electric organ has been characterized in
some details [4, 11]. The nicotinic acetylcholine receptor (AchR) found at the neuromuscular
junction is the autoantigen involved in the autoimmune disease Myasthenia gravis (MG). Owing to
its dual importance as a model autoantigen and as a model neurotransmitter receptor, its general
and antigenic structures have been extensively studied over the last 26 years. The AchR molecule
is a transmembrane glycoprotein (Mr ~290 kD) consisting of five homologous subunits in the
stoichimetry   2
 
    (embryonic) or   2      (adult), which form the action channel. The    subunit
carries in its N-terminal extracellular domain the main immunogenic region (MIR), a group of
conformationally dependent epitopes that seems to be a major target for the anti-AchR antibodies
in MG patients [12, 13].

AchR subunits are thought to be organized like barrel staves around the central ion channel in the
order       
 
, as shown in Fig 1B.2. The binding sites of acetylcholine (Ach) are formed at the
interfaces between    and   or   subunits. Because amino acids from both subunits contribute to
each of the two Ach binding sites, the properties of each of the Ach binding sites are somewhat
different. Both sites must have agonist bound for the ion channel to have a high probability of
flickering open for 1 or 2 ms. An antagonist bound to either site prevents activation.

Electron diffraction studies of Torpedo  electric organ AchRs have reached a resolution of 4.6 Å
[11]. The AchR is about 80 Å in diameter and 120 Å long and 65 Å extending on the extracellular
surface, 40 Å crossing the lipid bilayer, and 15 Å extending beneath the bilayer into the cytoplasm.
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The extracellular vestibule of the channel is about 25 Å in diameter surrounded by walls about 25
Å thick. The actual lumen of the channel through the lipid bilayer is quite narrow. The gate of the
channel is thought to be at its cytoplasmic end [13].










Fig 1B.2   The arrangement of subunits of muscle AchRs [3]

Nicotinic acetylcholine receptors, as well as other members of the ligand-gated ion channel
superfamily, present a very simple repertoire of functional properties. The AchR recognizes the
neurotransmitter Ach and upon binding, the intrinsically coupled ion channel is opened,
augmenting in turn the possibility of cations to cross the lipid membrane. Thus, after channel
opening, a new ionic concentration is found at the aqueous solution bathing the opposed faces of
the lipid bilayer of the cell. In particular, the extracellular liquid presents now a higher
concentration of K+  (efflux) and the cytoplasmic compartment has a higher content of Na+  (influx).
When the concentration reaches equilibrium a membrane depolarization is produced.
Depolarization of the membrane provokes a specific physiological response by each cell that is
involved. For instance, if the muscle membrane depolarization is large enough, an action potential
propagates from the neuromuscular junction all over the muscle fiber. During the propagating
action potential, the release of Ca2+  ions from intracellular stores in the muscle cell is stimulated.
The final response in the muscle is the contraction of its myofibrils [14].

All these biologically relevant AchR properties are triggered by the binding of the neurotransmitter
Ach. Upon binding, the receptor protein undergoes a conformational change. Several lines of
experimental evidence suggest that the AchR may exist in a minimum of four interconvertible
states. The tetrahedral diagram indicating the existence of at least four receptor states is shown in
Fig 1B.3. In the absence of agonists, most Torpedo  receptors (~80%) are in the resting state (Fig
1B.3, R). An additional about 20% of receptors is in the desensitized state (Fig 1B.3, D). The
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resting state is defined by the existence of an activatable closed ion channel. In the presences of
agonists, the receptor is activated (Fig 1B.3, A) in the microsecond to millisecond time frame. The
state presents an open ion channel and a low affinity for agonists (apparent dissociation constant
Kd  between 10   M and 1 mM). Concomitantly, in the prolonged presence of agonists the activated
receptor is commuted to an intermediate state (Fig 1B.3, I) in the 1-100 ms time scale and further
to a D state in the second to minutes time frame. No energy sources nor an ionic gradient is needed
to induce the conformational shift from the R to the D state [14].














Fig 1B.3   Diagram showing the dynamic of multiple conformational
states of the nicotinic acetylcholine receptor [14]

In the absence of the neurotransmitter Ach, shown here as empty circles, the AchR is in the resting
state (R), a conformation state where the ion channel is closed. The closed ion channel can be
opened upon binding of two Ach molecules to AchR. This active state (A) presents low affinity for
agonists. The transition from the R to A state is a fast process that proceeds in the microsecond and
millisecond time regime. In the prolonged presence of agonists, the AchR becomes refractive to
the agonist’s pharmacological action and thus, to the activation of its ion channel. In the Torpedo
AchR there exists two refractive closed ion channel states, the intermediate (I) and the desensitized
(D) state. Both states show high affinity for agonists and some antagonists. The transition from the
A to the I state is a slow process that is produced in 1-100 ms time range. The transition from the A
to D state has a much slower time course.
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1B.1.2   Research goals

The acetylcholine receptor (AchR) is a trans-membrane glycoprotein, consisting of 2  ,   ,  ,  
subunits. In muscle tissue of adults, the  -subunit is substituted by the  -subunit. A mature
 
-subunit has 437 amino acid residues containing the so-called main immunogenic region (MIR)-
a binding site of a polysaccharide. MIR located at residues 66 to 76 of   -subunit and contains an
Asn residue as the binding site of polysaccharide. MIR, as the target of AchR antibodies, plays an
important role in the autoimmune disease Myasthenia gravis. In order to investigate the
mechanism of Myasthenia gravis, researchers have attempted to obtain the relevant proteins by
gene technology. Unfortunately, the amount of AchR or its domain when expressed in engineering
bacteria usually is very low or the product occurs in the form of inclusion bodies. For improving
the efficiency of refolding and solubility of recombinant proteins, two recombinant vectors of
co-expressing the AchR   -subunit fragment and the chaperonin GroESL will be performed.  In this
part, plasmid pPR506 which contains the gene of the   -subunit domain of AchR and plasmid
pGE60 containing the gene of the chaperonin GroESL will be co-transferred into E. coli  DH5   and
co-expressed by the induction with IPTG. The receptor fragment could be coupled chemically to
gelonin and be employed in the treatment of Myasthenia gravis.

1B.2   Results and discussion

1B.2.1   Identification of the recombinant plasmids

The construction of pPR506 is shown in Fig 1B.4. To verify co-transformation of pPR506 and
pGE60, the two plasmids were transferred singly or doubly into E. coli  DH5  . Afterwards, the
plasmids were extracted and analyzed by 1% agarose electrophoresis (Fig 1B.5). The gel
confirmed indicated that the molecular weights of pPR506 and pGE60 of about 2.3 kb (Fig 1B.5;
A) and 6.0 kb (Fig 1B.5; C) respectively, while the co-transformed plasmid contained both pPR506
and pGE60 (Fig 1B.5; B) as deduced from their electrophoretic patterns.







Immunotoxins and Neurotrophins                                   

- 29 -













Fig 1B.4   Construction of plasmid pPR506
The target gene is a DNA fragment of AchR   -subunit residues from 1-120

By DNA sequence analysis, the fragment sequence in pPR506 is identical to the DNA sequence
deduced from the known amino acid residues of the AchR   -subunit domain. GAA encoding Glu is
the first amino acid of the domain and TCC encoding Ser is located at the 3'-terminus [15].












Fig 1B.5   Co-transformation of plasmid pPR506 and pGE60
Mr: λDNA/Hind III; A. pPR506 only (2.0 kb containing the AchR fragment); B. pGE60 (6.0 Kb) and pPR506
(Containing chaperonin GroESL and AchR fragment); C. pGE60 only (Containing charperonin GroESL).
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1B.2.2    Co-expression of the recombinant plasmids in E. coli

The engineering strain  E. coli  DH5  /pPR506+pGE60 was cultured in LB medium which contained
both ampicillin (Amp) and chloromycetin (Chl) at 37˚C, 220 r/m until the optical density (OD600nm)
of the culture reached about 0.5~0.6. Subsequently, IPTG was added for induction and
fermentation was continued for another 4 h at the same temperature. Pellets were harvested by
centrifugation (5000 r/m, 30 min) and sonicated in PBS. The supernatant was analyzed by
SDS-PAGE. Electrophoretic analysis of the culture products related that the expression of pPR506
had yield only a 13 kD band equal to the AchR   -subunit domain and the amount of expression
was also very low and those of pGE60 had two bands at 60 kD and 10 kD equal to the products of
GroEL and GroES respectively, while the co-expression product displayed four bands, of which
the 60 kD band could result from GroEL and 10 kD band from GroES as well as a 13 kD band that
is likely to be the   -subunit fragment (Fig 1B.6). The new band at 23 kD could be the complex
which contains 13 kD   -subunit fragment from the result of immunoblotting assay that both bands
of 13 kD and 23 kD were positive (Fig 1B.7).













Fig 1B.6   SDS-PAGE analysis for expression product
Lane1 and lane2: Co-expression products (AchR fragment and charperonin GroESL)
Lane3 and Lane4: Expression products by DH5  /pPR506 (Only AchR fragment)
Lane5: Expression products of DH5   (Control, no plasmids presented)
Lane6: Expression products by DH5  /pGE60 (Only charperonin GroEL/GroES)
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1B.2.3   Analysis of Western blots
   
After centrifugation of the sonicated mixture, the supernatant was run on 12% SDS-PAGE, the
components on the gel were transferred into a nitrocellulose membrane by sandwich
electrophoresis (Fig 1B.6, Lane1, 2, 3, 4 were transferred onto membrane). The membrane was
incubated with the primary antibody (mAb35; Part I·1C.2.3.4) and the second antibody (rabbit
anti-rat Ig 1:1000) respectively. Finally, the membrane treated as above was developed by
BCIP/NBT until the color of the target protein occurred and re-transferred into PBS to be fixed
immediately. Upon repetition of the experiments, the western blot was not always positive.







1B.2.4    Purification of products

After the supernatant was concentrated by Centriprep, not only some low molecular weight
proteins were partly extruded but also the sample was concentrated about 6 folds. The total protein
of cells was approximately 62 mg under the condition of the experiments. The concentrated sample
(about 5 mg) was loaded on Superose 12 HR10/30 on FPLC. The four eluted peaks were pooled
and run on SDS-PAGE respectively (Fig1B.8).












Fig 1B.8   Electrophoretic patterns of each
peak from HPLC by SDS-PAGE 
(The co-expression products of AchR fragment and
GroESL were purified with Superose 12 HR 10/30.)
L Lane1: Peak1, 60 kD (GroEL)
Lane2: Peak2, 23 kD and 13 kD (AchR fragment)
Lane3: Peak3, 10 kD (GroES).

Fig 1B.7   Western blot
The original SDS-PAGE picture was shown in Fig 1B.6.
The first antibody is mAb35 (Part I.C.2.3.4)
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1B.3    Summary

As described in previous work, the expression products of the acetylcholine receptor   -subunit or
its domain in bacteria usually resulted in inclusion bodies consisting of insoluble aggregates of the
proteins. It was then necessary to denature and renature the aggregates to obtain native protein.
However, it was reported that molecular chaperonins such as GroESL may facilitate renaturation of
denatured proteins to their native conformation. It was shown from our experiments that GroESL
slightly improved the correct expression of the acetylcholine receptor   -subunit fragment. Based
on the molecular weight of acetylcholine receptor   -subunit domain and GroES, it is very likely
that the 13 kD band in the SDS-gel belongs to the   -subunit fragment. The 23 kD would account
for a complex between the    subunit fragment and GroES, but there is no further evidence for such
a complex besides the Western blot (Fig 1B.7).

Our experiments clearly show that co-expression of the   -subunit fragment of AchR together with
GroESL leads to a soluble form of the receptor. However, the yields are very low and not
reproducible. The amount of receptor fragment was certainly not sufficient for chemical
cross-linking with gelonin. Hence, we tried to express the conjugate as a fusion protein as
described in Part I· C
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1C   Gene clone and expression of gelonin-acetylcholine receptor
 subunit domain


1C.1    Introduction

Conjugation between a RIP and an antibody is often used as a therapeutic agent. The antibody
could ideally deliver the cytotoxic compounds to the surface of cells, and immunoconjugates
consisting of a whole antibody or antibody domains linked to proteins that disrupt cellular protein
synthesis have been widely described [1]. Immunoconjugates have typically been constructed in
vitro  with antibodies and cytotoxic proteins by heterobifunctional cross-linking agents [2]. Recent
advances in antibody engineering, however, make it possible to express a variety of antibody
domains independently in microorganisms, and to express antibody domains as fusion proteins
with a variety of proteins such as enzymes, e.g. RIPs. Moreover, in such constructs the solubility
of hydrophobic proteins could be improved by the conjugation with highly soluble RIPs.

1C.1.1     Immune system

The immune system protects us from infections by microbes. It is composed of a number of
different cell types, tissues and organs. Many of these cells are organized into separate lymphoid
organs or glands. Since attack from microbes can come at many different sites of the body, the
immune system has a mobile force of cells in the blood stream which are ready to attack the
invading microbe wherever it enters the body.

All immunocompetent individuals have many distinct lymphocytes, each of which is specific for a
different foreign substance. When an antigen is introduced into an individual, lymphocytes with
receptors for this antigen seek out and bind it and are triggered to proliferate and differentiate,
giving rise to clones of cells specific for the antigen. These cells or their products specifically react
with the antigen to neutralize or eliminate it. The much large number of antigen-specific cells late
in the immune response is responsible for the memory of immunity.

There are of two major types of lymphocytes, B cells and T cells. T cells mature under the
influence of the thymus and, on stimulation by antigen, give rise to cellular immunity. B cells
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mature under the influence of bone marrow and give rise to humoral immunity that involves
production of soluble molecules, immunoglobulins. Interactions between T and B cells, as well as
antigen presenting cells, are critical to the development of specific immunity.

1C.1.1.1     Antigens and antibodies

Invading organisms have antigens which are recognized by the immune system. Antigens are
defined as substances which induce an immune response. They include proteins, carbohydrates,
lipids and nulcleic acids. An antigen molecule may contain a number of the same or different
antigenic determinants to which individual antibodies or cell responses are made. These antigenic
determinants or epitopes are the smallest unit of an antigen to which an antibody or cell can bind
(Fig1C.1). For a protein, an antibody binds to a unit which is about three to six amino acids whilst
for a carbohydrate it is about five to six sugar residues. Therefore, most large molecules possess
many antigenic determinants per molecule. However, these determinants may be identical or
different from each other on the same molecule.


 










Fig 1C.1   Antigenic determinants (epitopes) recognized by antibodies

Antibodies have a basic unit of four polypeptide chains -two identical pairs of light (L) chains and
heavy (H) chains- bound together by covalent disulfide bridges as well as by noncovalent
interactions. These molecules can be proteolytically cleaved to yield two Fab fragments (the
antigen binding part of the molecules) and an Fc fragment (the part of the molecule responsible for
effect functions). Both L- and H-chains are divided into V and C regions determining the fate of
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the antigen. The valence of an antibody is the number of antigenic determinants with which it can
react (Fig 1C.2).











Fig 1C.2   IgG immunoglobulin: basic 4 chain structure representative of all
immunoglobulins [3]

Different antibody classes with different biological activities have evolved to deal with antigens
with different properties and which enter the body at different sites. There is some overlapping in
their function and in where they are produced, but generally there is a division of labor among the
different antibody classes, e.g. IgA is most common antibody in mucosal secretions while IgM is
mainly found in the plasma, both are most effective at those locations. IgG, immunoglobulins
provide the bulk of immunity to most blood borne infectious agents, it is the only antibody class to
cross the placenta to provide humoral immunity to the infant. Allergic reactions are predominantly
associated with IgE.

1C.1.1.2     The antibody response

Antigen introduced into an individual binds specifically to B cells with receptors for that antigen.
In the presence of T cell help, these B cells clonally expand and some differentiate into plasma
cells which produce antibodies specific for the antigen that triggers the response. On first exposure
to antigen, a primary immune response develops resulting in production of IgM antibodies. This
usually is followed by an IgG immune response after a few days. This response is self-limiting and
will stop when antigen is no longer available to stimulate B cells. When antigen is reintroduced,
there are more antigen specific B cells which have differentiated to more responsive memory B
cells, resulting in a more rapid response and usually in IgG antibody production.
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Although antibodies produced by a single cell and its daughter cells are identical (homogeneous or
monoclonal; mAb), the response to a given antigen involves many different clones of cells and
thus, overall, is very heterogeneous (multiclonal). Considering the size of an antigenic determinant,
the number of determinants on a molecule, the number of different molecules on the
microorganism, the response to a microorganism results in a large number of different antibodies.
Even antibodies against a single antigenic determinant are heterogeneous, indicating that the
immune system is capable of producing many different antibodies, even to a single well-defined
antigenic determinant. This heterogeneity is essential for many of the protective functions of
antibodies.

1C.1.1.3    Cell mediated immunity

Cell mediated immunity (or T cell mediated immunity) is due to the direct action of T cells, and
can be transferred by cells. T cells have two major roles which are carried out by two distinct
subpopulations. T helper cells (Th) help other cells carry out their function, whilst cytotoxic T cells
(Tc) directly kill cells infected with intracellular microbes. Both Th and Tc need to interact directly
with the cells they are going to kill/help and they do this through specific recognition mechanisms.
This is mediated through interaction with MHC (major histocompatibility complex) on the surface
of the cell being for help and cytotoxicity.

1C.1.1.4    Cell recognition of self and non self

Cells of the immune system must be able to recognize and eliminate microbes and thus to
distinguish what is “foreign” from what is self. A fundamental requirement of the immune system
is that it destroys, eliminates or inactivates all foreign viruses, bacteria and parasites without
destroying self cells or molecules. Self tolerance is the state of immunological unresponsiveness to
self antigens. It is maintained through a number of different mechanisms in central and peripheral
lymphoid organs. The fundamental basis for self tolerance is that interaction of antigen with
immature clones of lymphocytes already expressing antigen receptors, would result in an
unresponsive state. In the thymus, self-reactive T cells are clonally eliminated by negative
selection as part of maturation of the T cell repertoire. In the bone marrow, self reactive B cells are
also eliminated. Lymphocytes escaping tolerance in the primary lymphoid organs are eliminated or
anergized in the peripheral lymphoid organs.
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1C.1.1.5   Autoimmunity and autoimmune diseases

Autoimmunity is an acquired immune reactivity to self antigens. The immune system has the
capacity to respond to virtually all molecules and/or cells. Although the capacity to respond to self
antigen is present in all of us, in most instances such responses result in tolerance or anergy,
indicating that the mechanisms must exist to prevent or subdue autoimmune responses. Moreover,
autoreactive T and B cells and autoantibodies are found in people who do not have autoimmune
diseases, demonstrating that immunological autoreactivity alone is not enough for the development
of disease. The mechanisms currently thought to prevent/dampen autoimmune responses include
inactivation or deletion of autoreactive T and B cells, active suppression by cells or cytokines,
idiotype/anti-idiotype interactions, and the immunosuppressive adrenal hormones, the
glucocorticoids.

Autoimmune diseases arise as the result of a breakdown in self-tolerance. Factors predisposing
and/or contributing to the development of autoimmune diseases include age, genetics, gender,
infections and the nature of the autoantigen. Combinations of these factors are probably important
in the development of an autoimmune disease. Autoimmune diseases are quite prevalent in the
general population, where it is estimated that approximately 3.5% of individuals are afflicted.

1C.1.2     Myasthenia gravis

Myasthenia gravis is a disorder in which autoantibodies to acetylcholine receptors at the
neuromuscular junction of skeletal muscle lead to AchR loss and muscle weakness. It is a classic
acquired autoimmune disease. What induces the autoimmune response to muscle AchRs in MG is
not known. The mechanisms may differ in various forms of MG. In most MG patients, the
immunogen is likely to be native muscle AchR or a closely related molecule because the spectrum
of autoantibody specificities in MG and EAMG is very similar [4]. Fetal-type AchRs may often be
the immunogen in MG, as indicated by the selective reaction with fetal AchRs found in many MG
patient autoantibodies [5, 6, 7]. Denatured AchR subunits or synthetic fragments of AchR subunits
are extremely inefficient at provoking EAMG because they lack the MIR [8, 9, 10].

The thymus is suspected to be the site of the initiation of the autoimmune response to AchRs in
MG because: (1) thymic myoid cells express fetal AchRs and other muscle proteins and low levels
of AchR may also be produced by some other thymic cells [11, 12, 13], (2) 70% of MG patients
exhibit thymus lymphoid follicular hyperplasia and exhibit germinal centers producing antibodies
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to AchRs [14, 15, 16], (3) thymectomy is often beneficial [17], (4) 10-15% of MG patients exhibit
thymoma [18], (5) the thymus is not hyperplastic or thymomatous in EAMG where the
autoimmune response is initiated with exogenous AchR [19], (6) transplant of fragments of MG
patient thymus to severe combined immunodeficiency (SCID) mice can transfer MG to the mice
[20]. However, the thymus is probably not the sole site for induction or maintenance of the
autoimmune response to AchR, thymectomy is not uniform or complete in its beneficial effect on
MG.

EAMG has been induced in many species by immunization with purified Torpedo electric organ
AchR [21]. AchR is quite immunogenic and EAMG has been induced by AchR [22]. Adjuvants are
usually used, but it is possible to induce EAMG with AchR even in the absence of adjuvants [23].
Among MG patients, the absolute concentration of antibodies to AchR does not correlate closely
with severity [24], but generally patients with only ocular manifestation have lower autoantibody
concentrations than do patients with generalized MG, and changes in an individual’s autoantibody
concentrations usually parallels changes in their clinical state [25]. The basic mechanisms by
which autoantibodies to AchR impair neuromuscular transmission appear to be very similar in MG
and chronic EAMG [26, 27].

1C.1.2.1   Cellular immune mechanisms in MG and EAMG

EAMG is caused by an antibody mediated autoimmune response, it is not surprising that
development of EAMG depends on the presence of B-cells. B-cell-deficient mutant mice are
resistant to induction of EAMG, but develop a normal T-lymphocyte-mediated immune response
and are susceptible to passively transferred EAMG mediated by a mAb to the MIR [28]. The T-cell
response in these mice lacking B-cells developed more slowly than it would have with antigen
presentation by B-cells as well as professional antigen-presenting cells. Antigen-specific B-cells
can be very efficient at presenting peptides from the native antigens that they bind with high
affinity.

Development of EAMG and MG depends on T-lymphocytes to cooperate with B-lymphocytes in
developing autoantibody-producing plasma cells, but which T-cell types are involved has been
more difficult to determine. CD4+ helper lymphocytes are necessary for the production of
antibodies to AchR in both EAMG and MG [29]. Using various methods with human MG patient
lymphocytes, different AchR epitopes have been identified. In various strains of rats and mice,
different prominent epitopes have also been identified [30]. Some of these have been used to
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induce tolerance and reduce induction of EAMG [31]. The dependence of these epitopes on the
genetics of the antigen-presenting proteins, T-cell receptors, and other components of the cellular
immune processing, recognition, and regulatory systems makes inbred rodent strains exquisitely
sensitive to immune regulation by AchR peptides and small mutations of these peptides. However,
it is unclear whether such subtleties will prove useful in predicting or manipulating the immune
response in the outbred human populations that comprise MG patients.

1C.1.2.2   Development of specific immunosuppressive therapies for EAMG and MG

There is currently no specific immunosuppressive therapy or cure for MG. Nonspecific
immunosuppressive therapy of MG with prednisone and other drugs, as well as by thymectomy
combined with symptomatic therapy using inhibitors of acetylcholinesterase, permits substantial
control of MG and has greatly reduced its mortality. There are significant side effects associated
with prolonged nonspecific immunosuppressive therapy. Because so much is known about the
antigenic structure of muscle AchRs and the pathological mechanisms of MG, it would seem
reasonable to hope for a specific immunosuppressive therapy, because it has been thought that MG
is the best characterized autoimmune disease [32]. Successful specific immunosuppression of MG
might be valuable not only for its benefit to MG patients, but also as a model for what might be
applied to others autoimmune diseases with well characterized autoantigens.

Some exotic approaches to inhibit autoantibodies to the MIR have been reported as potential
therapies for MG. Tzartos and coworkers proposed to use monovalent Fab fragments of mAbs to
the MIR to compete for binding of autoantibodies [33]. Due to lacking the Fc region, they cannot
fix complement and cause disruption of the postsynaptic membrane. Because they are monovalent,
they can not crosslink AchRs and cause antigenic modulations, as can bivalent F(ab)2  fragments
[34]. Fab fragments can prevent antigenic modulation of AchRs in cultured cells caused by mAbs
to the MIR or by MG patient sera [15]. Single chain Fv fragments of MIR mAbs and MG patient
autoantibodies have been expressed in bacteria, humanized, and selected for high affinity [35].
Unfortunately, Fab is very quickly cleared from circulation.

In addition there are other approaches taken for specific immunosuppression, such as Torpedo
AchR coupled with toxic drugs in order to try to kill B-lymphocytes that interact with it. It was
reported by Trommer that an AchR-conjugate i.e. AchR-gelonin obtained by chemical coupling
could be employed for selective elimination of specific lymphocytes involved in triggering and
maintenance of EAMG in vitro. The plant toxin gelonin was used which catalytically inhibits the
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elongation step of protein synthesis. In their study, it was indicated that a marked improvement of
clinical symptoms as well as a significant increase in functional AchR had occurred as compared to
treatment with AchR or gelonin alone or untreated rats with EAMG as determined 6-10 weeks later
[3].

1C.1.3   Research goals

Myasthenia gravis is an autoimmune disorder characterized by weakness and fatigability of
skeletal muscles. The pathogenesis of MG in human and experimental MG in animals (EAMG)
results from a reduction of the available acetylcholine receptors at neuromuscular junctions due to
an antibody-mediated autoimmune response. Although treatment of MG with general
immunosuppressive agents is reasonably effective, it may have numerous adverse side effects.
Ideally, treatment of MG should eliminate the specific pathogenic autoimmune response to AchRs,
without otherwise suppressing the immune system. The present study aims at a novel strategy for
specific immunotherapy of MG

AchR-toxin conjugates have been employed for selective elimination of specific lymphocytes
involved in triggering and maintenance of EAMG  in vivo  using the plant toxin ricin. Ricin as well
as gelonin catalytically inhibits the elongation step of protein synthesis. In the previous chapter
(Part I· 1B), we have described attempts for coexpression of the extracellular domain of the
 
-subunit of AchR with the chaperonin GroESL. It was then planned to couple the receptor
fragment chemically to gelonin. However, since the yields of soluble protein were very low, the
expression of a fusion protein composed of gelonin and AchR receptor fragment will be tried and
its biological activity be tested.

1C.2   Results and discussion

1C.2.1   Cloning gelonin-AchR fragment gene

Based on our earlier work and the relevant data obtained, a strategy of recombinants pET-GA and
pJLA-GA was employed as shown in Fig 1C.3. The beginning two plasmids pUC-gel I and
pUC-gel II-AchR were provided by Ya-Wei Shi [25, 1A.4]. In order to obtain a gelonin-AchR
fusion gene, the gel II-AchR fragment from pUC-gel II-AchR was inserted into the opened
pUC-gel I by double enzymic digestion with XbaI/EcoRI and ligation, to be a fusion construct,
named pUC-GA. After identification of the construct, a band of 1196 bp equal to the fragment
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expected has been found on the gel which indicated that the recombinant was the one we
anticipated (Fig 1C.4).



























Fig 1C.3   Construction of expression vector for gelonin-AchR
 (pUC-gel I, pUC-gel II-AchR were provided by Ya-Wei Shi et al [25, in 1A.4])
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Table 1C.1   Reaction system of enzymatic digestion of pUC-gel I/pUC-gel II-AchR

Compounds Volume
PUC-gel I or pUC-gel II-AchR   30 µl
XbaI 2 µl
EcoRI   2 µl
10x buffer2# 4 µl
H2Obidest   2 µl
                  * The reaction mixture was incubated at 37
 
 for 2 h
        
Table 1C.2   Ligation system for pUC-GA

Reaction mixture Volume
PUC-gel I (opened) 0.5 µl
Gel3+4+AchR (1196 bps) 6 µl
10xT4  DNA ligase buffer 1 µl
T4  DNA ligase 1 µl
H2Obidest 1.5 µl
*The reaction mixture was incubated at 26˚C for 2 h and continuously at 16˚C overnight










In addition, two expression plamids, pET-GA and pJLA-GA were produced by inserting
gelonin-AchR DNA fragment cut by NdeI/EcoRI into the vectors pET28a or pJLA503 following
the routine DNA cloning technology. By double cleavage with NdeI and EcoRI as well as DNA
sequence determination, the successful production of two expression recombinants, pET-GA and
pJLA-GA was demonstrated (Table 1C.3).
Fig 1C.4   Identification of pUC-GA
Mr. DNA marker (  DNA/HindIII cut)
Lane 2: pUC-GA digested with XbaI/EcoRI
(The fragment gel II+AchR should be 1196 bps)
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Table 1C.3   The ligation system for pET-GA and pJLA-GA

          1  2  3
pET28a 30 µl pUC-GA   30 µl pJLA503 30 µl
NdeI 2 µl NdeI 2 µl NdeI 2 µl
EcoRI 2 µl EcoRI 2 µl EcoRI 2 µl
10x buffer2# 4 µl 10x buffer2# 4 µl 10x buffer2# 4 µl
H2Obidest 2 µl H2Obidest 2 µl H2Obidest 2 µl


         pET28a (opened)          Gelonin-AchR           pJLA503(opened)




pET28a (opened) 1 µl  pJLA503 (opened) 0.7 µl
Gel+AchR (1546 bps ) 5 µl    Gel+AchR (1546 bps ) 7 µl
10x T4DNA ligase buffer 1 µl  10x T4DNA ligase buffer 1 µl
T4DNA ligase 1 µl    T4DNA ligase 1 µl
ddH2O 2 µl  ddH2O 0.3 µl
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1C.2.1.1   Identification of pET-GA and pJLA-GA

Recombinant plasmids of pET-GA or pJLA-GA were transferred into host strain E. coli BL21,
DH5α or DHI, respectively. After incubating the strains on LB plates (ampicillin or kanamycin),
20 colonies were separately taken out in 5 ml LB medium with the proper antibiotics at 37°C in a
shaker. After 12 h, the plasmids were extracted. The correct recombinants were obtained as shown
by cleavage of the recombinant plasmid with NdeI/EcoRI and subsequently agarose gel
electrophoresis, a fragment of 1546 bp corresponding to gelonin-AchR was detected (Fig 1C.5 and
Fig 1C.6).


Ligation
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1C.2.2   Expression

20 ml LB medium containing kanamycin or ampicillin was inoculated with one colony and shaken
at 37°C overnight. After 12 h, the pre-culture was transferred into 1000 ml LB (Kan or Amp). The
broth was cultured to reach an optical density (OD600nm) of about 0.7-0.8 and immediately
induced with IPTG for strain E. coli BL21/pET-GA at the same temperature for 4 h or induced at
42°C for 3 h for strain E. coli DH5α/pJLA-GA. The cells were harvested by centrifugation and
re-suspended in 50 mM phosphate buffer pH7.0. After sonication and centrifugation, the mixture
was run on 12% SDS-PAGE to identify the products. The results showed that the fusion product of
gelonin-AchR fragment obviously forms inclusion bodies and the concentration of soluble protein
is very low (Fig 1C.7). However, the product of strain E. coli DH5α/pJLA-GA by inducing at
42°C could not be confirmed whether it formed the target protein because the corresponding band
was not detected on the SDS-PAGE (Fig 1C.8). Therefore, only BL21/pET-GA was used for
further studies.
Fig 1C.5   The products of pET-GA  by
double endonuclease cleavage
Lane1: pET-GA with NdeI/EcoRI
(The fragment of gelonin-AchR should be 1546 bps)

Fig 1C.6   The products of pJLA-GA by
double endonuclease cleavage
Lane1: pJLA503
Lane2: pJLA503 with EcoRI
Lane3: pJLA503 with NdeI/EcoRI
(The fragment of gelonin-AchR should be 1546 bps)
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Fig 1C.7   Expression of pET-GA in E. coli BL21
(Transformed cells of BL21 with plasmid pET-GA were plated on LB media plates. Single
                  colony was picked and screened for expression on SDS-PAGE)
Lane1: Strain E.coli BL21; Lane2: BL21/pET-GA uninduction
Lane3: Precipitate after induction and sonication
Lane4: Supernatant after induction and sonication
Lane5: BL21/pET-GA with induction











Fig 1C.8   Expression of pJLA-GA in DH5α
(Transformed cells of DH5α with plasmid pJLA-GA were plated on LB media plates. Single
                      colony was picked and screened for expression on SDS-PAGE)
Lane1: Culture of DH5α
Lane2: Culture of DH5α/pJLA-GA with induction
Lane3: Precipitate after induction and sonication
Lane4: Supernatant after induction and sonication
48 kD
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1C.2.3   Purification and identification of supernatant

The pellets of cells from 1 L LB medium were re-suspended in 30 ml, 50 mM, phosphate
buffer pH7.2, containing 1 mM PMSF, 20 mg lysozyme (25,000 U/mg), at RT 1-1.5 h. Then 2
mM DTT was added before sonication. It was sonicated under the condition of 30 sec, 15x on
ice. Then the mixture was separated by centrifugation (14,000 r/m, 30 min). Two parts were
collected, one was the supernatant and the other was the inclusion body. Usually, there are
about 130 mg of total protein in 1 L LB to be obtained in supernatant, while 80 mg or so
proteins existed in the precipitate. Then the two parts were processed separately.

1C.2.3.1   Isolation of supernatant

Supernatant in 50 mM PBS, pH7.2, 1 mM PMSF and 2 mM DTT, adjusted with 1 M NaCl
and 0.25 M (NH4)2SO4,   was loaded on Phenyl Sepharose 6 ff column and stepwise eluted
with 0.5 M NaCl, 50 mM PBS pH7.2 and H2O (Fig 1C.9). A 48 kD product was eluted in the
water fraction as shown by SDS-PAGE analysis (Fig 1C.11).











Fig 1C.9   Purification of gelonin-AchR on Phenyl-Sepharose
Sample: Supernatant after sonication; Column: 0.9 x 10 cm
Equilibration buffer: 50 mM PBS, pH7.2, 1M NaCl and 0.25 M (NH4)2SO4
Elution buffer: 0.5 M NaCl; 50 mM PBS pH7.2; H2O
Detection: A280nm; Flow rate: 1min/ml
Peak 1: Flow through; Peak 2: 0.5 M NaCl in 50 mM PBS pH7.2
Peak 3: 50 mM PBS pH7.2; Peak 4: Water
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Then the fraction in H2O was concentrated and loaded on cation and anion-exchange resin.
Unfortunately, the product cannot be purified either on cation or on anion resins, even if the
pH value was changed from 4 to 10. According to the resolution on SDS-PAGE, the sample
from hydrophobic column was applied on Superose12 (AKTA purifier, Pharmacia) (Fig
1C.10). Though the purification efficiency was not satisfying, some pure products were
detected by SDS-PAGE (Fig 1C.11).












Fig 1C.10   Purification of gelonin-AchR by Superose 12 on AKTA Purifier
Column: Pre-packed Superose 12 HR 10/30 from Phamacia; Sample: 100   l (4 mg/ml) of peak 4 of previous
column (See Fig 1C.9); Elution buffer: 50 mM PBS pH7.2; Flow rate: 0.5 ml/min; Fraction size: 0.5 ml. No
24#, 25#  containing a 48 kD protein.









Fig 1C.11   Electrophoretic patterns of fusion protein on 12% SDS-PAGE
Lane1: Uninduced pET-GA/BL21; Lane2: Induced pET-GA/BL21; Lane3: Inclusion bodies; Lane4:
Mixture after sonication; Lane5: Peak 4 from phenyl-Sepharose (See Fig 1C.9); Lane6: Fraction 24#  from
Superose 12 HR 10/30 (See Fig 1C.10).
48 kD
24#
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1C.2.3.2   Western blots of gelonin-AchR

For further confirmation, Western Blots were performed. Gelonin-AchR was run on 12%
SDS-PAGE and the native gelonin (30 kD) isolated from seeds of Gelonium multiflorum to
which a standard protein marker had been added was used as a positive control for the
Western blots. The antigelonin polyclonal antiserum was used as first antibody.
Peroxidase-conjugated sheep anti-mouse Ig diluted 1:4000 was added and reacted with the
substrate, BCIP/NBT in the western blot assay. It is indicated from Fig 1C.12 that there is a
clear band (30 kD) of native gelonin in Lane Mr. and recombinant gelonin-AchR was blotted
in Lane 1.











Fig 1C.12   Western Blots of gelonin-AchR
Left: SDS-PAGE; Right: Western blot
Mr. containing native gelonin (30 kD) as control.
Lane1: Pure recombinant gelonin-AchR
The first antibody is mouse anti-gelonin polyclonal antiserum

1C.2.3.3   Discussion

Based on the electrophoretic patterns of the supernatant centrifuged from sonication mixture,
a 48 kD protein band was found in spite of limited quantity, compared with the same band
from the precipitate. In order to obtain the fusion protein quickly, a process was chosen to
purify the soluble part. It was indicated from the experimental results that the step of
hydrophobic chromatography was more effective, not only many impurities were washed out,
but also the 48 kD band was concentrated. Subsequently, strong and weak cation exchangers
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(SP-Sepharose, CM-Sephadex) and strong and weak anion exchangers (Q-Sepharose,
DEAE-Sephadex) were tried for the purification, but with little success. Finally, a procedure
of gel filtration on Superose 12 was applied to purify the fraction eluted from
Phenyl-Sepharose. Though the resolution of gel column was not so ideal, a pure 48 kD
product was finally obtained as shown by SDS-PAGE analysis.

1C.2.4   Denaturation and refolding of inclusion bodies

The inclusion bodies were washed three times with 40 ml B-PER reagent which was diluted with
PBS by 1:10 and centrifuged at the same condition, then were solubilized in 6 M guanidine
hydrochloride (GuHCl), 20 mM Tris-HCl (pH8.0), 5 mM DTT, 2 mM EDTA, incubated at room
temperature for 2 h and stored at 4˚C  overnight. After centrifugation, the solution containing
denatured proteins was collected and stored at 4˚C  until purification.

1C.2.4.1   Preliminary purification of denatured proteins

The denatured proteins were separated by size-exclusion chromatography as follows: Sephacryl
S-200 column (2.2x100 cm) pre-equilibrated with 5 M GuHCl, 20 mM Tris-HCl pH8.0 (column
buffer) was passed with 22 mg (11 mg/ml) of denatured proteins. The column was eluted with
column buffer at the flow rate of 0.5 ml/min. Fractions were further examined by SDS-PAGE.











Fig1C.13   A profile of denatured mixture of gelonin-AchR fragment
 on Sephacryl S-200
Sample: 22 mg (11 mg/ml in 6 M GuHCL); Equilibration buffer: 5 M GuHCL in 20 mM Tris-HCL pH8.2;
Column: 2.2 x 100 cm; Flow rate: 1 ml/min; Fraction: 3 ml; Detection: 280 nm (OD: 1.0)
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Fig1C.14   Electrophoretic patterns of the fractions on SDS-PAGE
Lane1: Denatured mixture of gelonin-AchR fragment
Lane2-9: Different fractions from peak 1 in Fig 1C.13


1C.2.4.2   Refolding of fusion protein

Method 1

The denatured sample was stepwise diluted from 5 M, 3 M to 1 M guanidine in 20 mM
Tris-HCl pH8.2, then dialyzed against 20 mM Tris-HCL (pH8.2), 2 h and the precipitate was
spun down at 14,000 r/m for 30 min. 1 mM GSH (glutathione) and 0.1 mM GSSG (oxidized
glutathione) were added into the diluted solution for refolding, gently shaking at 4˚C for 12 h.
After that, this solution was dialyzed against 20 mM Tris-HCL, pH8.2 thoroughly. This
soluble protein was purified on Q-Sepharose column, eluted with a stepwise gradient: 0.1 M
NaCl, 0.2 M NaCl, 0.5 M NaCl and the target protein could be eluted from 0.1 M NaCl As
Fig 1C.15. Normally 100   g soluble protein could be obtained form 1 mg denatured protein.
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 Fig 1C.15A   An elution diagram of renatured gelonin-AchR fragment
Sample: Refolded gelonin-AchR fragment fusion protein; Flow rate: 1min/ml
Matrix: Q-Sepharose (3×4 cm); Equilibration buffer: 20 mM Tris-HCl, pH8.2
Elution: Stepwise with 0.1M NaCl, 0.2M NaCl, 0.5M NaCl;
Peak 1: 0.1M NaCl, Peak 2: 0.2M NaCl, Peak 3: 0.5M NaCl;
Detection: 280 nm (OD: 0.2).

Fig 1C.15B   Electrophoretic patterns of refolded gelonin-AchR fragment protein
eluted from Q-Sepharose column
Lane1: Fraction of refolded gelonin-AchR fragment
Lane2: Mixture after sonication.
Method 2

 The denatured inclusion bodies were mixed with the final concentration of 20 mM Tris-HCl pH8.0,
5 mM DTT, 2 mM EDTA, 2 mM GSH and 0.2 mM GSSG by rapid votexing at room temperature
to a final concentration of 400   g /ml protein and 1 M GuHCL. Incubation was performed at 4ºC
for about 16 h. Normally more than 200   g refolded protein could be obtained from 1 mg
denatured protein as Fig 1C.16.


48 kD
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Fig 1C.16   Electrophoretic patterns of refolded protein
Lane1: Denatured gelonin-AchR fragment fusion protein
Lane 2-4: Refolding fusion protein in different amount (5   g, 3   g, 1   g)

1C.2.4.3   ELISA assay

The mAb ( 35, 192, 198) used in this study are directed against the extracellular region of AchR
 
 subunit. The antibodies were derived from rats immunized with intact AchR with either human
muscle (mAb 192, 198) or Electrophorus  electricus electric organ (mAb 35). The mAb 35 exhibits
nice cross reactivity with human AchR.

The different fractions eluted from Sephacryl S-200 were analyzed by SDS-PAGE. The fraction
corresponding to the immunotoxin (48 kD) was pooled and refolded as described in 1C.3.4.2. In
order to examine whether the product is a toxin, the refolded protein was assessed by ELISA.
Wells of microtiter plates were coated with 2   g samples either refolded or the unfolded fusion
protein in refolding buffer or PBS buffer plus coating buffer till 100   l incubated at 4°C overnight.
The coated wells were washed 3 times with PBST for 1.5 h at room temperature. Monoclonal
antibodies diluted with PBS were added to each well and incubated for 2 h at room temperature.
Afterwards each well was washed with PBST for 3 times before adding 100   l of
peroxidase-conjugated rabbit anti-rat Ig (dilution 1:1000) in PBS for 1 h at room temperature. The
wells were continuously washed with PBST for four times respectively. The bound mAb was
measured by peroxidase activity with P-nitrophenyl phosphate as the substrate. The color
developed in 30 min or so was measured at 405 nm.

48 kD
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The three mAbs ( 192, 198, 35) [36], partly or completely recognize the native conformation of
human AchR (Table 1C.4), were used for a binding assay. The binding ability of mAb 198 is
significantly higher than the background level which refers using BSA as the negative control and
positive control of AchR isolated from Electrophorus electric organs. However, the binding affinity
of mAb 198 to the denatured protein was rather low. Binding of mAb 198, 192 was increased with
decreasing concentrations of GuHCl (Table 1C.5).

Table 1C.4   ELISA assay

Antibodies Fusion protein
(Recombinant)
AchRa
(Torpedo)
BSAb
mAb192 0.110.01 - 0.010.01
mAb198 0.710.01 0.530.01 0.010.01
mAb35 0.2 00.02 0.130.01 0.010.01
Polyclonal antigelonin 0.120.02 - 0.010.01
               a. Positive control; b. Negative control

    Table 1C.5   mAb binding by the various refolding conditions

Refolding protein in MAb192 MAb198
5M GuHCl 0.030.01 0.220.02
2.5M GuHCl 0.030.01 0.290.01
1.25M GuHCl 0.110.01 0.710.02
1M GuHCl 0.100.01 0.640.01
BSA (control) 0.010.01 0.050.01

   mAb 35 reacts with native AchR of human and Torpedo
   mAb 192 reacts with native human AchR
   mAb 198 reacts with AchR of human and Torpedo either native or denatured

1C.2.4.4   Effect of gelonin-AchR fragment on protein synthesis

To examine the toxicity of the fusion protein, an in vitro  translation assay in a reticulocyte lysate
containing globin mRNA was performed with a series of samples diluted from 3.16 x 10-8  M to
3.16 x 10-13M. The protein synthesis was measured by the incorporation of 14C-valine into this
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protein. It was shown from Fig 1C.17 that gelonin alone and gelonin-AchR possess similar toxicity
with IC50  of gelonin at 35 ng/ml and of gelonin-AchR at 30 ng/ml respectively.











Fig 1C.17   Comparison of the cell-free protein synthesis (rabbit reticulocyte) inhibitory
activity of recombinant gelonin and its fusion protein (Refer to previous Fig
1A.14 in 1A.2.6).

1C.3   Summary

Immunotoxins as first proposed by Paul Ehrlich as ‘magic bullets’ in cancer treatment are
conjugates composed of tissue-specific antibodies and a toxin. Similarly, conjugates of
auto-antigens with toxins could be used for treatment of autoimmune diseases. The auto-antigen
moiety would direct the toxin to lymphocytes with an affinity and specificity for this
macromolecule.

In part I·1C a conjugate of the extracellular portion of the   -subunit of the AchR (amino acids
1-181) with the single chain RIP gelonin was constructed and expressed as fusion protein for a
potential treatment of Myasthenia gravis. This autoimmune disease is characterized by
autoantibodies mainly against the AchR from the neuromuscular endplate.

In this study, we constructed a recombinant plasmid with the vector pET28a and the gene of
gelonin and   -subunit fragment of AchR. The fused protein was expressed in E. coli  and obtained
mainly in the precipitate in the form of inclusion bodies as shown by SDS-PAGE. After
solubilizing the inclusion bodies in denaturing buffer containing 6 M GuHCl or 8 M urea, several
refolding conditions were tried to obtain the functional protein. However, most of these procedures
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were unsatisfactory. The most efficient method by which the fusion protein was obtained in a
native-like conformation, was to dilute the denatured protein into 1 M GuHCl with refolding buffer
containing GSH, GSSG and DTT at room temperature. The purified and refolded fusion protein
binds mAb 35, 192, 198 as well as polyclonal antigelonin. It also inhibits protein biosynthesis with
an IC50  similar to gelonin itself. Given the specificity of the AchR for target lymphocytes, the
conjugate could be an effective therapeutic agent for the treatment of the autoimmune disease
Myasthenia gravis.
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Part II   Neurotrophins
2.1   Introduction

2.1.1   Neurotrophins

The development and maintenance of the nervous system depend on proteins by the name of
neurotrophic factors (Table 2.1). The neurotrophic factors, a subclass of cell growth factors, act on
neurons as well as other non-neuronal cells. As depicted in Figure 2.1, the subclass contains at
least three distinct families: neurotrophins, i.e. nerve growth factor (NGF), brain-derived
neurotrophic factor (BDNF) and neurotrophins 3, 4/5 (NT3, NT4/5); the neuropoietic cytokine, i.e.
ciliary neurotrophic factor (CNTF) and the fibroblast growth factors (FGF), i.e. acidic and basic
FGF [1]. The role of neurotrophic factors in cell development has been investigated extensively in
cultured cells from different brain regions. These studies indicate that survival of cultured
embryonic neurons from different brain regions may require one or more neurotrophins.

Table 2.1   Examples of proteins reported to have neurotrophin properties


Proteins with well-documented
neurotrophin activity
Proteins with putative
neurotrophin activity
Acidic fibroblast growth factor (aFGF) Cholinergic neuronal differentiation factor (CDF)
Basic fibroblast growth factor (bFGF) Epidermal growth factor (EGF)
Brain-derived neurotrophic factor (BDNF) Heparin binding neurotrophic factor (HBNF)
Ciliary neruotrophic factor (CTNF) Insulin
Interleukin 1, 3 and 6 (IL-1, 3, 6) Insulin like growth factor (IGFs)
Neurotrophin 3 (NT3) Protease nexin I and II
Nerve growth factor (NGF) Transforming growth factor alpha (TGF  )
Glia-derived neurotrophic factor (GDNF)
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Fig 2.1   Classification of neurotrophic factors


2.1.2   Neurotrophin receptors

The members of the neurotrophin family are all specific for their various receptors. Based on the
binding ability of neurotrophins and their receptors, they can be divided into two classes: high
affinity receptors which are tyrosine receptor kinases (Trk) and the low affinity receptor p75 [2].
High affinity receptors encoded by the Trk primitive cancer gene are trans-membrane proteins with
molecular weights of 120-160 kD. They exist in three subclasses, TrkA, TrkB and TrkC. As
indicated in Fig 2.2, TrkA could bind to NGF, TrkB has been demonstrated to bind brain-derived
neurotrophic factor (BDNF) and neurotrophin 4/5 as well as TrkC bind to neurotrophin 3. The low
affinity receptor, p75 with a molecular weight of 75 kD, is composed of an extra-cellular region, a
transmembrane structure and an intra-cellular region. All the members of neurotrophins can
interact with the receptor p75 as described in Fig 2.2.
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                     Fig 2.2   Neurotrophins and their receptors [2]

2.1.3   Human neurotrophin 3

The human neurotrophin 3 (hNT3) is one of the most important members of the neurotrophin
family. It can provide nutrition for neurons and repair damaged neuronal cells. Recently,
neurotrophin research has made some progress with respect to the structure and function of the
receptors including hNT3 and its mechanism in the central and peripheral nervous system.
2.1.3.1   Molecular characteristics of hNT3

The human brain-derived neurotrophic factor, BDNF and NT3 are relatively small proteins with 
119 to 130 amino acids. The conserved regions (60% overall homology) and the disulfide bond
sites of the four proteins are the same (see Fig 2.3), leading to very similar 3D structures [3, 4].
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Fig 2.3   Comparison of three dimensional structure of NGF, BDNF and NT3 [4]

The variable amino acids are predominantly located in four regions: three hairpin regions (residues
29-35, 43-49, 92-97) in the upper ring and the 58-68 amino acid region in the lower ring of these
molecules. Each member of the neurotrophins has independent bioactivity and affinity to different
receptors [5].

The amino acid residues important for binding to p75 and the Trk receptor are located in the
variable regions of neurotrophin 3. Those regions can be divided into seven different parts: the
amino terminal region (residues 1-9), a carboxy terminal region (residues 111-118) and the loop
regions I, II, III, IV, V (residues 23-25, 40-49, 59-66, 79-88, 94-98). By knockout and targeted
gene-mutation, amino acid mediated interactions of NT3 and TrkC were determined, which
include Arg8 and Tyr11 of the amino-terminal region, Thr22 of region I, amino acids 39-48 of
region II and Lys80 and Gln83 of region IV [6].

2.1.4 Purification of the recombinant proteins

Since the 90’s of the last century, the discovery of protein self-splicing has changed our view of the
flow of genetic information from DNA to protein [7, 8]. Protein splicing occurs at the
post-translation level of protein biosynthesis. After synthesis of a precursor protein, an internal
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protein domain (termed the intein) is precisely excised from the precursor and two external
domains (termed exteins) are ligated together forming a peptide bond between the exteins [9, 10,
11]. Thus, two proteins are derived from a single gene, one of which is not collinear with the
original open reading frame. After a 454-residue intein in the 69 kD vacuolar membrane ATPase
subunit of Saccharomyces cerevisa (Sce VMA intein) was initially discovered, almost 100 inteins
have been identified in eubacterial, archae and eukaryotic unicellular organisms. The alignment of
inteins has revealed that most inteins are bi-functional proteins, containing an endonuclease
domain and a splicing element, while a few inteins (termed mini-intein) ranging in size from 134
to 198 amino acids lack the endonuclease region. Intein as a splicing element has some conserved
amino acids at the junctions, which play an important role in protein splicing as shown in Table
2.2.

Table 2.2   Comparison of conserved amino acids at the intein splice junctions [12]

N-domain
(N-Extein)   
Protein splicing element
       ( Intein)
C-domain
 (C-Extein)
Sce               AILYVG C  FAKGT (454) NQVVV    H N C  GERGN
Ctr                VIIYVG C  FTKGT (471) NMALV    H N C  GERGN
Mtu             KVVKNK C  LAEGT (440) EGVVV    H N C  SPPFK
TliI2             KVLYAD S  VSGES (390) NNILV     H N T  DGFYA
TliI1              IKLLAN  S  ILPNE (538) GLLYA     H N S  YYGYM
PspI1              IKILAN S   ILPEE (537) GFLYA    H N S  YYGYY
MIP              RGTRRA S  ILPEE (537) GSLYA     H N S  GNSAF
Sce: Saccharomyces cerevisiae vacuolar ATPase subunit intein
Ctr: Candida tropicalis vacuolar ATPase subunit intein
Mtu: Mycobacterium tuberculosis RecA intein
Tli I1 / I 2: Thermococcus litoralis DNA polymerase intein-1 and intein-2
PsP: Pyrococcus sp. GB-D DNA polymerase intein
MIP: Psp pol. intein inserted between MBP and paramyosin

Residues with hydroxyl or thiol groups (Ser, Cys, Thr) are present at both splicing junctions. The
hydrophobic amino acids His-Asn at the C-terminus of the intein are essential residues for the
function of inteins. Though the correct conformation of intein is necessary for protein splicing, the
residues at the junctions are crucial [12, 13, 14, 15]. Based on the protein splicing mechanism
proposed by Xu and coworkers [16, 17], a branched intermediate is formed as shown in Fig 2.4.
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The splice process comprises four tightly coupled nucleophilic displacements via a branched
intermediate. The amino acid residues (Cys, Ser, Thr) at two splice junctions and an invariant Asn
at the intein C-terminus are essential for the intein-catalyzed splicing reaction. Splicing is initiated
by an N-S (or N-O) acyl rearrangement involving Cys (or Ser) at the N-terminus of the intein,
generating a reactive thioester (ester) bond. Transesterification occurs at the thioester (ester)
formed in step1 and the side chain of residue (Ser, Cys or Thr) at the beginning of the C-extein.
Finally, the ester (or thioester) linkage between the exteins undergoes a spontaneous acyl
rearrangement to form a native peptide bond via a branched intermediated [18, 19]. It was reported
from Xu’s and Chong’s work at New England Biolabs that the formation of a thioester linking the
N-extein and the intein is still possible if the conserved Asn at C-terminus of the intein is mutated
to Ala to block C-terminal cleavage. Conversely, if the CyS1 at N-terminus of the intein is mutated
to Ala1 to block N-terminal cleavage, splicing at C-terminus of the intein is also performed (Fig
2.5). Based on this principle, a target protein could be obtained from a fusion product,
protein-intein or intein-protein, by a thioester bond cleavage. Therefore, this system may facilitate
the purification of recombinant proteins, which may not easily be accessible otherwise.

Purification of recombinant proteins by the use of affinity tags is a convenient and widely used
technology. A variety of affinity tags have been employed, including Schistosoma glutathione
S-transferase (GST), E. coli maltose-binding protein (MBP), Staphylococcus protein A,
polyhistidine and calmodulin-binding peptide etc. After affinity absorption, the tag is usually
cleaved from the fusion protein by treatment with a site-specific protease [20, 21]. However, the
use of proteases has limited the application of many purification systems. First, cleavage by
proteases is not always specific, resulting in cleavage at secondary sites; second, the cleavage is
sometimes inefficient due to the inaccessibility of the cleavage site in the fusion protein; third,
additional purification steps are required to obtain the target protein. To avoid and improve the
limitations, a protein splicing system in vitro was introduced to purify recombinant proteins by
intein self excision as described above. In order to make affinity absorption possible, an affinity
tag in the form of a chitin binding domain (CBD) coding region was inserted into the open reading
frame of the intein at the N-terminus or C-terminus [22, 23]. In such case, the expression product
has an extremely high affinity to chitin beads. During protein purification, the fusion protein
consisting of a target protein-intein-CBD complex or a CBD-intein-target protein complex, can be
cleaved by thiol reagents such as DTT or
 
-ME directly in chitin bead columns. Using the
self-cleavable intein system, a target protein could then be obtained from crude extract in a one
step purification procedure as shown in Fig 2.5 and 2.6.
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Fig 2.4   Proposed protein splicing and cleavage pathway for the mini-intein [23]
 Protein splicing occurs via four concerted nucleophilic replacements:
    Step1: Formation of a linear thioester intermediate at the N-terminus of the intein by
an N-S acyl rearrangement at Cys1. 
Step2: Formation of branched intermediate by transesterification involving attack by
the side chain of Ser155 on the thioester formed in step1.
Step3: Excision of the intein by peptide bond cleavage coupled to Succinimide formation by
Asn154 at the C-treminus of intein.
Step4: Spontaneous O-N acyl rearrangement of the transitory ligated exteins to form a stable amide bond.
Protein splicing for other inteins presumably proceeds by four analogues chemical steps, except that
the Cys residues may be replaced by Ser or Thr or vice versa. N-terminal splice junction cleavage
can occur by hydrolysis or nucleophilic attack of the thioester or ester linkage. Cyclization of Asn154
can proceed independently when the normal route of the splicing reaction is inhibited
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Fig 2.5   Intein-mediated protein purification system [23]

The target proteins fused to intein can be cleaved at N-terminus or C-terminus of the intein by DTT.
In order to form an affinity tag, a chitin binding domain (CBD) was co-expressed with the fusion
protein together.
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Fig 2.6   A schematic representation for single column purification of
       recombinant proteins using a self-cleavable affinity tag [24]
Upper: A diagram for the process of culture, induction, affinity absorption and DTT cleavage
Lower: The electrophoresis patterns of sample from the corresponding parts on SDS-PAGE.
1. Protein marker;
2. Uninduced cells;
3. Clarified crude extract from induced cells;
4. Flow through;
5.  Quick DTT wash;
6-9. Fractions of eluted protein after stopping column flow and inducing a self-cleavage
 reaction at 4°C overnight;
10. SDS stripping of remaining proteins bond to chintin beads column.

2.1.5   Research goals

The human neurotrophic factor 3 (hNT3) is a member of the expanding family of neurotrophins
which can stimulate the growth, differentiation and survival of peripheral and central neurons
during the development or the damage of nerve cells. hNT3 is a 13.6 kD protein corresponding to
119 amino acid residues and usually exists as a dimer in vivo. The dimer can bind to cell surface
receptors and perform its biological function. Therefore, hNT3 could serve as a potential
therapeutic agent for nerve diseases, such as peripheral neuritis. Because the amount of hNT3 in
cells or organelles is very limited, it is imperative to obtain hNT3 by gene engineering technology
in higher amounts.
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Protein splicing is a post translational processing event involving the precise excision of an internal
protein segment, the intein, from a primary translation product with concomitant ligation of the
flanking sequence, the exteins. Since the mechanism of protein splicing in vitro was reported, the
research and application of protein splicing has been largely expanded to intein-mediated protein
purification. The goal of this work was to amplify the hNT3 gene from genomic DNA of human
whole blood by PCR and inserted it into an expression vector pTXB1 which contains an
intein-chitin binding domain (CBD) construct. After expression we could purify the fusion protein
of hNT3-intein-CBD with a chintin bead column and try to get pure hNT3 under intein splicing
conditions by a one step procedure. Finally, the biological activity of hNT3 and hNT3-intein-CBD
can be determined by the outgrowth of nerve fiber round dorsal root ganglia of chicken embryos.

2.2   Results and discussion

2.2.1   Amplification and identification of the human neurotrophin 3 gene

2.2.1.1   Preparation of genomic DNA from human whole blood

Fresh human whole blood was rapidly mixed with buffer in an Eppendorf tube, and the supernatant
was removed by centrifugation. The precipitate was resuspended in potassium containing buffer.
The mixture was incubated to digest the cells. After inactivation of protease K, the sample was
used directly as the template for PCR (see 3.4.1).

2.2.1.2   Amplification of human neurotrophin 3 gene by PCR

The primers used in amplification of human neurotrophin 3 gene by PCR were designed according
to the reported DNA sequence for the human neurotrophin 3 gene , and synthesized by
Shanghai Biotechnol. Co. Ltd (see 3.4.2)
Primer A   FW. 33 mers (10   mol / L):
5’-GAA TCC CAT ATG TAC GCG GAG CAT AAG AGT CAC-3’
Primer B   RV. 34 mers (10   mol / L):
5’-GCA GTC GAC TCA TGT TCT TCC GAT TTT TCT CGA C-3’
The amplified product was analyzed on a 1.5% agarose gel. As shown in Fig 2.7, the PCR reaction
yielded a 380 bp fragment which corresponds to the reported size for the human neurotrophin 3
gene.
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Fig 2.7   hNT3 gene amplified by PCR
  Mr: pBR322 DNA/HinfI cut;
            Lane1-2: hNT3 products by PCR (380 bp)

2.2.2   Construction of recombinant pGEM-hNT3

2.2.2.1   Background of pGEM-T vector

The pGEM-T Easy Vector is a high-copy plasmid widely used for direct cloning of PCR products.
It contains a multiple cloning site and permits blue/white screening of recombinants. It can express
a foreign gene from the promoters, T7 and SP6. Most importantly, this linear vector contains an
extra thymidine (T) base at each of the 3’ ends. This allows for direct ligation with DNA fragment
products from PCR reactions using Taq polymerase, which normally adds a single extra adenine
(A) to the 3’-end of an amplified DNA strand.










Fig 2.8   pGEM-T easy vector map (See 3.1.2)
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2.2.2.2   Construction of pGEM-hNT3

The conditions for the ligation reaction are described in part III (3.4.3). The reaction mixture was
then transformed into E. coli  DH 5α by a heat shock procedure (see 3.3.2) and plated on LB agar
medium plates supplemented with ampicillin and Xgal for white/blue screening. After incubation,
a number of blue single colonies were picked and grown in LB (ampicillin) medium. The
recombinant plasmids were extracted from the cells as described in Part III (3.3.3) and the
insertion of hNT3 gene was confirmed as described below.

2.2.2.3   Confirmation of pGEM-hNT3

The plasmid pGEM-hNT3 was digested with NdeI and/or SalI and resolved on a 1.5% agarose gel
(see 3.4.3, Table 3.6). The results showed that the single digestion (with NdeI) yielded a single
band, while the double digestion (with NdeI and SalI) produced an extra band around 380 bp. The
results suggested that the human neurotrophin 3 fragment amplified by PCR was correctly inserted
into the pGEM-T vector (Fig 2.9).



















Fig 2.9   Electrophoresis patterns of pGEM-hNT3 cut by restriction endonucleases
Mr1:   DNA/HindIII cut 
Lane1: pGEM-hNT3
Lane2: pGEM-hNT3 cut by SalI (only one band occurring)
Lane3: pGEM-hNT3 cut by NdeI/SalI (a 380 bp band corresponding to hNT3)
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2.2.2.4   DNA sequence analysis

DNA sequence analysis for pGEM-hNT3 was performed with an ABI Prism 377 DNA Sequencer.
A primer corresponding to the T7 promoter sequence was used as the starter. The result (Fig 2.10)
showed that the sequence of the cloned hNT3 and the sites of restriction digestion were identical to
those that were reported. Meanwhile, the upstream and downstream sequences of the gene were
also identical to the precursor of hNT3 in genomic DNA sequence.

DNA sequence of hNT3

CATTGGGCCC
TCCCATATGT
TGACAGTGAG
GGGGACACCA
GTCAAACAAT
AAACGGTTGC
CATCCCAAAC
GGCTGGCGGT
AAAAATCGGA
AGGTCGACCA
ATTCTATAGT
GACGTCGCAT
ACGCGGAGCA
AGTCTGTGGG
GGTCACGGTG
ATTTTTATGA
AGGGGTATTG
CTACGTCCGA
GGATACGGAT
AGAACATGAG
TATGGGAGAG
GTCACCTAAA
GCTCCCGGCC
TAAGAGTCAC
TGACCGACAA
CTGGGGGAGA
AACGCGATGT
ATGATAAACA
GCACTGACTT
AGACACGTCC
TCGACTGCAA
CTCCCAACGC
TAGCTTGGCG
GCCATGGCCG
CGAGGGGAGT
GTCATCGGCC
TCAAAACGGG
AAGGAAGCCA
CTGGAACTCT
CAGAGAACAA
TGTGTGTGTG
TCACTAGTGC
GTTGGATGCA
TAATCATGGT
CGGGATTGAA
ACTCGGTATG
ATCGACATTC
CAACTCTCCC
GGCCGGTCAA
CAGTGCAAAA
TAAACTCGTG
CCTTGTCGAG
GGCCGCCTGC
TAGCTTGAGT










Fig 2.10   The DNA sequence of hNT3 (upper panel) and the corresponding restriction
enzyme sites in hNT3 (lower panel)
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2.2.3   Construction and expression of pTXB-hNT3 [25]

2.2.3.1   Background of pTXB1  

The pTXB1 vector used in this study is a substitute of pTYB (New England Biolabs) catalogue #
6701).  In this vector, the Sce VMA1 intein is replaced with the mini-intein (see Fig 2.4). In order
to confine the self-splicing to the N-terminus of the intein only, the conserved Asn residue at the
C-terminus of the intein has been mutated into Ala to block the C-terminal splicing. This vector
also contains the ampicillin resistance gene and a chitin binding domain coding region. Protein
expression of the engineered strain is IPTG-inducible.





MCS:       -Nde1-Nhe1-Nru1- Sal1-Not1-EcoR1-Xho1-Sap1-
Fig 2.11   A diagram of inserted sites in MCS of pTXB1
The target gene was inserted into the MCS between NdeI and SapI

2.2.3.2   Construction of pTXB-hNT3

2.2.3.2.1   hNT3 gene amplified from pGEM-hNT3 by PCR 

pGEM-hNT3 was used as the template to amplify the hNT-3 gene for subcloning into the pTXB1
vector. The primers used were as follows:

FW   primer  (33 mers)
5’-GGA GCT CATATG TAC GCG GAG CAT AAG AGT CAC-3’
RV   primer  (34 mers)
5’-GGT CGC TCT TCG GCA TGT TCT TCC CAT TTT TCT C-3’

The primers were designed to introduce a codon (ATG) at the 5’-end of the open reading frame of
the target gene, and an extra Cys codon (TGC) at the 3’-end of the open reading frame of the target
gene. The latter design is to produce a protein splice site at the N-terminus of the intein. The
amplified product was resolved on a 1% agarose gel (Fig 2.12).
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Fig 2.12   Electrophoretic patterns of the PCR product on 1% agarose gel.
 Mr1: λDNA/HindIII cut and   X174 DNA/HaeIII cut; 
Lane1: Recombinant plasmid pTXB-hNT3
Lane2: hNT3 PCR products (380 bp)
Mr2: pBR322 DNA/BstN I cut

2.2.3.2.2   Construction and screening of pTXB-hNT3  

The PCR product was digested with NdeI/SapI, and then force-cloned into the identically restricted
endonuclease sites of pTXB1. The ligation reaction was performed at 12 oC overnight using T4
DNA ligase. The mixture was then transformed into E. coli 2566 and plated on LB agar medium
plates supplemented with ampicillin. Several single colonies were picked and grown in LB
medium supplemented with ampicillin, and the protein expression was initiated by the addition of
IPTG. The positive colonies were screened by SDS-PAGE. As shown in Fig 2.13, a prominent 41
kD band corresponding to the molecular weight of hNT3-intein-CBD fusion product was clearly
visible for all of the colonies screened.








Fig 2.13   Electrophoresis patterns of expression products on 12% SDS-PAGE
(Transformed cells of E. coli 2566 with plasmid pTXB-hNT3 were plated on LB media plates. Single
colony was picked and screened for expression on SDS-PAGE)

Mr: Broad range 7702# from NEB;
Lane1: E. coli 2566/pTXB-hNT3 Uninduced;
Lane2-7: E. coli 2566/pTXB-hNT3 induced with IPTG
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2.2.3.3   Identification of pTXB-hNT3

The recombinant plasmid was extracted from several positive colonies and subjected to enzyme
digestion analysis. As the SapI site in the hNT3 gene was deleted after subcloning into pTXB1,
NdeI, SpeI and PstI in the open reading frame of the fusion construct were used to determine
whether the hNT3 gene was inserted into the pTXB1 vector. The results (Fig 2.14) showed that
three bands corresponding to 0.4 kb, 1.2 kb, and 0.8 kb were generated following the digestion by
NdeI/SpeI, NdeI/PstI, and SpeI/PstI respectively, confirming the correct insertion of the human
neurotrophin 3 gene. Meanwhile, DNA sequence analysis of the recombinant plasmid also
indicated that the sequence of human neurotrophin 3 was the same as reported previously (Fig
2.10).








Fig 2.14   Enzymatic cleavage diagram of pTXB-hNT3 on 1% agarose gel
       Mr1:   DNA/HindIII cut and   X174 DNA/HaeIII cut; 
         Lane1 and Lane3: Recombinant plasmid pTXB-hNT3
         Lane2: pTXB-hNT3 cut by SpeI/PstI (ca.0.8 kb fragment)
         Lane4: pTXB-hNT3 cut by NdeI/PstI (ca.1.2 kb fragment)
         Lane5: pTXB-hNT3 cut by NdeI/SpeI (ca.0.4 kb fragment)
Mr2: pBR322 DNA/BstNI cut

2.2.3.4   Expression and purification

20 ml LB medium supplemented with ampicillin was inoculated by a single colony of the
engineered strain, E. coli  2566/pTXB-hNT3 and incubated at 37 oC overnight. This small culture
was used to inoculate 1000 ml LB broth supplemented with ampicillin. When the culture reached
an OD600nm of 0.6-0.7, the inducer IPTG was added to a final concentration of 1 mM and the
culture was continuously incubated at 30 oC for another 3 h. Cells were then harvested by
centrifugation and the pellets were stored at –70 oC or used immediately.
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The pellets from 1 L culture were re-suspended in 30-35 ml of ice cold 0.05 M Hepes buffer
containing 0.5 M NaCl and 0.1 mM EDTA (pH 8.0), which were then subjected to sonication and
centrifugation. The target protein was found mainly in the form of aggregates. To remove the
non-target proteins, the inclusion bodies were washed once time with 0.05 M Hepes buffer and
three times with B-PER (Bacterial Protein Extract Reagent) diluted by 1:10 with the Hepes buffer
after centrifugation.

2.2.3.4.1   Denaturation and renaturation of inclusion bodies  

The function of a protein critically depends on its three dimensional structure. Inclusion bodies, on
the other hand, are merely aggregates of unfolded polypeptide chains, which have no defined
conformation or function. To obtain functional proteins, these inclusion bodies can be solubilized
with 8 M urea or 6 M guanidine hydrochloride (GuHCl) and the soluble protein can often be
refolded under stringent conditions such as low temperature and low protein concentration etc. In
this experiment, the inclusion bodies from 1 L culture were solubilized in 6 ml of 0.05 M Hepes
buffer containing 1 mM EDTA, 100 mM DTT, and 8 M urea (pH 8.0) at room temperature for 2 h,
followed by centrifugation at 20,000 r/m for 20 min to remove precipitates. After determination of
the total protein concentration, the solution was gradually diluted by stepwise addition of 0.05 M
Hepes buffer containing 2 mM glutathione (GSH), 0.2 mM oxidized glutathione (GSSG) and 0.5
M L-arginine (pH 8.0) to reduce the urea concentration to 1 M. The protein concentration was then
further adjusted to 100   g/ml by dilution, and the polypeptides were allowed to refold at 16 oC for
24 h with slow stirring. Subsequently, the refolded protein was applied to a chintin beads column
for affinity purification as described in the next step.

2.2.3.4.2   One step purification of refolded hNT3-intein-CBD 

In the vector pTXB1, a 0.2 kb chitin binding domain (CBD) coding region is located at the
C-terminus of the intein for producing an affinity tag. Therefore, the fusion product,
hNT3-intein-CBD can bind to the chitin beads column by affinity adsorption. The refolded
proteins dialyzed against 0.05 M Hepes and 1M urea (pH8.0) were slowly applied to the column
with 10-15 ml bed volume of chitin beads at a flow rate of 0.5 ml/min. Then the column was
washed to remove the non-specifically absorbed proteins. 50 mM DTT was then added to start the
self-splicing procedure. To allow for the efficient cleavage, the column was closed after 30-40 ml
DTT buffer had entered, and the reaction was allowed to proceed for 48 h at 25ºC. On the basis of
the mechanism of intein-inducible excision, the fusion protein, hNT3-intein-CBD was spliced by
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DTT directly in the affinity column and the cleaved hNT3 was eluted from the column. The results
of SDS-PAGE showed that a 14 kD band corresponding to human neurotrophin 3 had occurred
(see lane 9 of Fig 2.15). The recovery of refolded human neurotrophin 3 is about 10% of the total
proteins loaded on the affinity column. Because of incomplete cleavage under the above conditions,
most of hNT3-intein-CBD fusion product was retained in the column. This part could be extracted
with in 1% SDS and subsequently investigated by SDS-PAGE (see lane 12 in Fig 2.15).












Fig 2.15   The electrophoresis patterns of the expression product and
 its renaturation on SDS-PAGE
1. Protein marker: The broad protein marker from NEB
2. E. coli  2566/pTXB-hNT3 Culture of un-induced cells
3. E. coli  2566/pTXB-hNT3 Culture of induced cells (Fusion protein: 41 kD)
4. Mixture of induced cells after sonication
5. Supernatant after step 4 centrifugation
6. Precipitates from step 4 dissolved in 8 M urea
7. Loading sample on affinity column after refolding
8. Flow through and wash the column with column buffer
9-10 Spliced sample eluted from the column cleaved by DTT (hNT3: 14 kD)
11. Fusion protein control
12. Strip out from affinity beads in 1% SDS
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2.2.4   Construction and expression of pJLA-hNT3

2.2.4.1   Construction of pJLA-hNT3

The previous experiments showed that it was possible to obtain hNT3 from plamid pTXB-hNT3,
however, the yield of 10% of refolded product was low. Therefore we constructed a new plasmid
where the expression of the target protein was under the control of a heat inducible promoter. The
vector pJLA503 is a plasmid containing a heat inducible promoter. The expression of engineered
strains can be achieved by swiftly shifting the incubation temperature to 42C. According to both
polylinkers of pTXB1 and pJLA503, the hNT3-intein-CBD DNA fragment from pTXB-hNT3 cut
by NdeI/BamHI was inserted into the opened pJLA503 using T4  DNA ligase as shown in Fig 2.16.














Fig 2.16   Construction of pJLA-hNT3

2.2.4.2   Identification of pJLA-hNT3

After the recombinant was transformed into host  E. coli  BL21, the engineered strain was cultured
in LB medium supplemented with ampicillin. The recombinant plasmid was extracted and digested
by NdeI and BamHI as described in Part III (3.3.3). The results in Fig 2.17, lane 2 showed two
bands on a 1% agarose gel, one corresponds to the original opened pJLA503 of about 5.0 kb and
the other is the fusion gene, hNT3-intein-CBD, about 1.2 kb, lane 3 showed only one band that
was found after single cleavage with Nde1 (Fig 2.17).
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Fig 2.17   Identification of pJLA-hNT3
Lane1: pJLA-hNT3 only
Lane2: pJLA-hNT3 digested with NdeI/BamHI
(hNT3-intein-CBD, about 1.2 kb)
Mr1: ΦX174DNA with HaeIII cut
Lane3: pJLA-hNT3 digested with NdeI (5.0 kb)
Mr2: λDNA with HindIII cut

2.2.4.3   Expression and purification

The engineered strain E. coli BL21/pJLA-hNT3 was cultured in LB medium supplemented with
ampicillin at 37C. When the culture reached an OD600nm of 0.8-0.9, the incubation temperature
was immediately raised to 42C for another 3 h. The pellets were treated as described in 2.2.3.4.
The target protein, hNT3-intein-CBD (41 kD) was also found in the form of aggregates or
“inclusion bodies” (see lane1 in Fig 2.18). The amount of inclusion bodies could reach nearly 50%
of the total protein in host cells as judged by optical density scanning of SDS-PAGE in Fig 2. 18.
According to the principle of protein splicing, the sonicated cells were directly cleaved by DTT
and run on SDS-PAGE. After staining with coomassie brilliant blue (CBB), three bands can be
seen on the gel (see lane2 in Fig 2.19). Based on their molecular weights, 41 kD corresponds to
hNT3-intein-CBD, the 14 kD and 27 kD bands obviously correspond to hNT3 and intein-CBD
respectively. It is indicated that the fusion protein can also be excised by DTT, though the cleavage
reaction is quite incomplete (Fig 2.19A). After denaturation and renaturation as well as affinity
absorption as described in section 2.1.4, a 14 kD band product, hNT3 was also obtained (Fig
2.19B).
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Fig 2.18   The expression products of engineered strain  E. coli  BL21/pJLA-hNT3
Lane1: Precipitates after sonication and centrifugation (fusion protein: 41 kD)
Lane2: Supernatant after sonication and centrifugation
Lane3: Mixture culture after induction (fusion protein: 41 kD)
Lane4: Mixture culture uninduced
Lane5: Strain  E. coli BL21 without recombinant plasmids













Fig 2.19   Electrophoresis patterns of the fusion product cleaved by DTT
A. Mixture culture after sonication (Lane1, hNT3-intein-CBD) directly added 100 mM DTT (Lane2, containing
hNT3-intein-CBD, Intein-CBD, hNT3) or 50 mM DTT (Lane3 same as lane 2) for splicing. B. The refolded
protein (hNT3-intein-CBD) was subjected to the column and eluted from a chitin bead column after DTT
cleavage (Lane1, only 14 kD hNT3)


41 kD
14 kD
27 kD
hNT3
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2.2.5    Bioactivity assay

The biological activity of neurotrophin 3 in the conditioned media was measured by its ability to
stimulate the outgrowth of nerve fibers of the dorsal root ganglia obtained from 8-day-old chicken
embryos. The detailed protocol is described in 3.5.4

In general, several drops of collagen from guinea pig tail were spread out on the bottom of each
sterile culture bottles. After drying up in an incubator at 37C, 3 ml DMEM medium was added to
each bottle and then incubated in 5% CO2-incubator overnight. The following day, two separate
ganglia were taken into each culture bottle and mixed with 500   l diluted sample. The diluted
procedure results in a series of dilution factors of 1 (original sample), 3×10-1,  10-1, 3×10-2, 10-2 etc.
Finally, the cultured bottles were incubated in a 5% CO2-incubator up to 24 h.

The patterns of fiber outgrowth from the explanted ganglia in different amounts of neurotrophin 3
were examined with a phase contrast microscope. One biological unit is defined as the
concentration of neurotrophin 3 which corresponds to the outgrowth of nerve fibers caused by 15
ng human nerve growth factor under the same conditions. We found that 80 ng of
hNT3-intein-CBD complex and 25 ng of the recombinant hNT3 equaled one biological unit. Based
on the molecular weights, hNT3-intein-CBD and hNT3 are almost equally active in stimulating
nerve cell growth.















Fig 2.20    Bioassay In vitro.
Dorsal root ganglia obtained from 8-day-old chick
embryos were exposed for 20 h to different samples.
A. Control; B. 80 ng hNT-3-intein- CBD; C. 25 ng
hNT3 alone.
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2.3    Summary

This part deals with the cloning and expression of the hNT3 gene, especially employing a new
method to swiftly purify the expression product, hNT3 by intein-inducible excision. hNT3 is one
of the important members of the neurotrophin family. Due to its various potential applications, it is
important to be able to obtain rather high amounts of the protein. Most likely, molecular cloning
technology is an ideal process to reach the goal. However, many protocols for purifying
recombinant proteins have some limitations, for instance, high cost proteases, complicated
purification processes, etc. In this case, we tried to introduce a new purification strategy, using a
protein self-splicing system which has been developed since 1990s of the last century to purify
target proteins from crude expression products by a one step operation. The recombinant hNT3 has
been expressed and purified by other researchers, however, hNT3 fusion with the intein gene and
purification by the protein splicing system is a rather new approach.

As far as the up-stream process is concerned, first a pair of primers was designed according to the
reported DNA sequence of the hNT3 gene. The total DNA of fresh human whole blood was used
as the template to amplify the gene by PCR. The amplified gene was inserted into the vector
pGEM-T which could directly be ligated with the PCR product. Then the correct structure of
pGEM-hNT3 was confirmed by double cleavage with NdeI/SalI and DNA sequence analysis. After
that, a second pair of primers was designed on the basis of MCS of pTXB1, and pGEM-hNT3
served as the template to amplify the hNT3 gene by PCR. The amplified hNT3 DNA fragment was
inserted into vector pTXB1which contains the intein DNA fragment attached to a chitin-binding
domain (CBD) coding region. The engineered strain E. coli 2566/pTXB-hNT3 was cultured in LB
medium supplemented with ampicillin. After induction with IPTG, the target protein,
hNT3-intein-CBD was mainly found in the form of inclusion bodies. In addition, the other
construct, pJLA-hNT3 with temperature induction was tried. However, the expression product of
the engineered strain E. coliBL21/pJLA-hNT3 also aggregated just as in case of the above
engineered strain.

Protein purification and bioactivity assay are the two main steps in downstream processes. Because
the expression products of both engineered strains mentioned above are all “inclusion bodies,” it
was necessary to make the aggregates soluble under the conditions of denaturation and
renaturation. The inclusion bodies were dissolved in 8 M urea and then the solution of unfolded
polypeptides was diluted stepwise into 1 M urea with Hepes buffer and GSH, GSSG, L-arginine
for refolding. Finally the refolded protein was applied to an affinity column of chitin beads and
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washed to remove non-specifically absorbed proteins. In order to obtain pure hNT3 by
intein-inducible excision, DTT was loaded onto the affinity column and kept in the column for 48
h at 25. Then the column was eluted with Hepes buffer, and hNT3 was collected as monitored
proteins with coomassie brilliant blue. By the preliminary assay of the biological activity, it was
shown from the results of the nerve fiber outgrowth of the dorsal root ganglia of chicken embryo
that hNT3 and hNT3-intein-CBD exhibit the same bioactivity. One biological unit for the fusion
protein, hNT3-intein-CBD and its cleavage product, hNT3, required about 80 ng or 25 ng,
respectively, compared to 15 ng of the standard sample, human nerve growth factor.
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Part III   Materials and methods

3.1   Materials

3.1.1   E. coli strains

E. coli  strains  Genotype Refs
BL21 (DE3) F-ompTgal (dcm) (lon) hsdSB
(rB-mB- ; an  E. coli  B strain) with
DE3, a   prophage carrying the
T7 RNA polymerase gene
[1]
DH5   F- /endA1 hsdR17 (rk-mk-) supE44
thi-1 recA1 gyrA (Nalr) relA1
(laclZYA-argF) U169 deoR ( 
80dlac(lacZ)M15)
[2]
DHI F- supE44recA1 endA1gyrA96 (Nalr)
Thi1 hsdR17 (rk-mk+)
[3]
ER2566 F- - fhuA2 (lon) ompT LacZ::T7
genel gal sulA11  (mcrC–mrr)
114 :: lS10R (mcr73::miniTn10)2 R
(zgb-210 ::Tn10)1 (Tets) end A1 (d
cm)
[4]


3.1.2   Plasmids

Plasmids  Genotype Refs
pGEM-T Ampr, f1 ori, T7 promoter, SP6 transcription,
MCS10-113,  LacZ, Lac operate
[5]
pGEM-hNT3 Ampr, f1 ori, T7 promoter, SP6 transcription, LacZ,
Lac operator, hNT3 (380 bp)
This work
pTXB1 Ampr, Ptac, T7 promoter, M13ori, MCS1525-1575, LacZ,
Intein-CBD
[6]
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pTXB-hNT3 Ampr,  Ptac, T7 promoter, M13ori, LacZ, Intein – CBD
– hNT3
This work
pJLA503 Ampr, PRPL, cIts857, induction by shifting
temperature, fd-transcription terminal, MCS12-358
[7]
pJLA-hNT3 Ampr, PRPL, cIts857, induction by shifting
temperature, fd-transcription terminal, hNT3
This work
pUC118 Ampr, LacZ, LacP, MCS8-376  [8]
pUC-gel I Ampr, LacZ, LacP, gelonin1+2 (345 bp) Ya-Wei Shi et al.
Provided
pUC-gel II Ampr, LacZ, LacP, gelonin3+4 (415 bp) Ya-Wei Shi et al.
Provided
pUC-gelII-AchR Ampr, LacZ, LacP, gelonin3+4+AchR (1196 bp) Ya-Wei Shi et al
provided
pUC-gel Ampr, LacZ, LacP, gelonin (760 bp) This work
pET28a Kanr, f1 origin, T7 promoter, Lac operator,
MCS158-203, LacI, pBR322 origin
[9]
pET-gel Kanr, f1 origin, T7 promoter, Lac operator, LacI,
pBR322 origin, gelonin (760 bp)
This work
pET19b-AchR Ampr, LacZ, LacP, AchR (1-181 aa) In Trommer’s lab
pPR506 Ampr, Ptrc, pBR322 origin, AchR (1-120 aa) In Trommer’s lab
pGE60 Chlr, Plac, Phs, pBR322 origin, GroES, GroEL In Trommer’s lab
pUC-GA Ampr, LacZ, LacP, gelonin+AchR (1546 bp) This work
pET-GA Kanr, f1 origin, T7 promoter, Lac operator, LacI,
pBR322 origin, gelonin+AchR (1546 bp)
This work
pJLA-GA Ampr, PRPL, cIts857, induction by shifting
temperature, fd-transcription terminal, gelonin+AchR
(1546 bp)
This work
  Further details about these plasmids are given in the relevant chapters of this thesis

3.1.3 Enzymes

β-agarase 10 U/µl New England Biolabs
EcoRI 20 U/µl New England Biolabs
HindIII 20 U/µl New England Biolabs
KpnI 10 U/µl New England Biolabs
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NcoI 20 U/µl New England Biolabs
NdeI 20 U/µl New England Biolabs
PstI 10 U/µl MBI Fermentas
SalI 20 U/µl New England Biolabs
SpeI 10 U/µl New England Biolabs
XhoI 10 U/µl MBI Fermentas
XbaI 20 U/µl New England Biolabs
T4 DNA Ligase 20 U/µl New England Biolabs
T4 DNA Polymerase 5 U/µl New England Biolabs
Taq Polymerase 5 U/µl New England Biolabs
Pyrophosphatase 4 U/µl MBI Fermentas
      The digestions were carried out in the New England Biolabs buffer system.

10 x NEB buffer 1:                                  10 x NEB buffer 2 :
 100 mM  Bis Tris-Propane-HCl                        500 mM  NaCl
 100 mM  MgCl2                                                   100 mM  Tri-HCl
 10 mM   Dithiothreitol                               10 mM   Dithiothreitol
 pH 7.0                                             pH 7.9

10 x NEB buffer 3 :                               10 x NEB buffer 4 :
 1 M      NaCl                                   500 mM  Potassium acetate
 500 mM  Tris-HCl                                200 mM  Tris-acetate
 100 mM  MgCl2                                100 mM  Magnesium acetate
 10 mM   Dithiothreitol                               10 mM   Dithiothreitol
 pH 7.9                                           pH 7.9 


         

3.1.4 Oligonucleotides

The oligonucleotide fragments for gelonin were synthesized by MWG Biotech AG, Ebersberg. The
delivered lyophilisate was solubilized in H2Obidest  prior to use. The concentration was checked by
UV absorption measurement (See 3.3.7) 
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Gelonin 1 fragment:  1×120 mer and 1×119 mer

5’-CCCTGCAGTA ATAACATATG GGCCTGGATA CCGTGAGCTT
CAGCACCAAA GGCGCCACCT ATATTACCTA TGTGAACTTC
CTGAACGAAC TGCGTGTGAA ACTGAAACCG GAAGGCAACA-3’

3’-TGACTTTGGC CTTCCGTTGT CGGTACCGTA AGGCGACGAC
GCATTTTTTA CGCTACTAGG CCCGTTTACG AAGCACGACC
ACCGCGACTC GTTGCTATTG CCGGTCGATC GCCATGGGG-5’


Gelonin 2 fragment:  1×97 mer and 1×98 mer

5’-AAGAATTCGC TAGCGGAAAT TGCGATTGAT GTGACCAGCG
TGTATGTGGT GGGCTATCAG GTGCGTAACC GTAGCTATTT
CTTCAAAGAT GCGCCGG-3’ 

3’-AAAGAAGTT CTACGCGGCC TACGCCGCAT ACTTCCGGAC
AAGTTTTTGT GGTAATTTTG GGCAGACGTA AAGCCGCCGT
CGATAGGCTC AGATCTCG-5’ 


Gelonin 3 fragment:  1×120 mer and 1×119 mer

5’-AATCTAGAAG GCGAAAAAGC GTATCGTGAA ACCACCGATC
TGGGCATTGA ACCGCTGCGT ATTGGCATTA AAAAACTGGA
TGAAAACGCG ATTGATAACT ATAAACCGAC CGAAATTG-3’

3’-GATATTTGGC TGGCTTTAAC GCTCGTCGGA CGACCACCAC
TAAGTCTACC ACTCGCTTCG CCGCGCAAAG TGGAAGTAAC
TTTTGGTCTA AGCATTGTTG AAGGTCGTCG CTTAAGGC-5’
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Gelonin 4 fragment:  1×120 mer and 1×119 mer

5’-CGGAATTCGT CCGGCGAACA ACACCATTAG CCTGGAAAAC
AAATGGGGCA AACTGAGCTT CCAGATTCGT ACCAGCGGCG
CGAACGGCAT GTTCAGCGAA GCGGTGGAAC TGGAACGTGC-3’

3’-CGCCACCTTG ACCTTGCACG CTTGCCGTTT TTTATAATAC
ACTGGCGCCA CCTAGTCCAC TTTGGCTTTT AACGCGACGA
CTTTAAGCAG CTGTTTCTAG GCTTTATTAT TCCATGGGG-5’
Shadow indicates the complement bps

3.1.5 Media and antibiotics

Agar Oxoid LTD, England
Tryptone peptone Oxoid LTD, England
Yeast extract Oxoid LTD, England
Ampicillin Amersco
Kanamycin-sulfat Amersco
Chloramphenicol Amersco


3.1.6 Chemicals

30% Acrylamide-bis Sangon Company, Canada
B-PER Bacterial Reagent Pierce
DTT Sigma
EDTA Sigma
GSH Sigma
GSSG Sigma
IPTG American Bioanal
L-arginine·HCl Sigma
L-valine Sigma
Phenol/Chloroform/Isoamylalcohol (P/C/I) Sangon Company, Canada
PMSF Amersco
Tris (tris(hydroxymethyl)aminomethane) Sangon Company, Canada
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X-gal American Bioanal
NBT Promega
BCIP Promega
1640  Sangon company, Canada
DMEM Sangon company, Canada
Rabbit reticulocyte lysate translation systems Promega
     The chemicals not specified here were available in the groups and were of AR grade.

3.1.7 Other materials

Agarose American Bioanal
BSA (10 mg/ml) New England Biolabs
Cell free lysate Promega
λ-DNA  New England Biolabs
λ-DNA/Eco  47I-ladder New England Biolabs
λ-DNA/Hind  III-ladder New England Biolabs
Nerve growth factor Boehringer
QIAprep Spin Miniprep Kit Qiagen
QIAGEN Nucleotide Removal Kit Qiagen
QIAGEN Gel Extraction Kit Qiagen
SP-Sepharose ff Pharmacia
Q- Sepharose ff Pharmacia
Phenyl-Sepharose  Pharmacia
Superose 12 Pharmacia

3.1.8 Equipment

Centrifuges Table centrifuge  SanYo
 SP-21 with a fixed angle rotors MSE
 Biofuge28RS Heraeus
Incubator Air shaker THZ-82 JiangSu, China
Thermocycler Gene ATAQ PCR System  Phamacia
Other equipment: GDS Gene company
 pH meter 720 Orion

CO2-Incubator  Heto
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 Autoclave SanYo
 Chromatography system  LKB
 AKTA purifier Pharmacia
 CT60e Freezing dryer  Heto
 Sonicator Zhejian, Xin-zhi

3.2   Cultivation and storage

3.2.1   Media, agar plates and antibiotics for the cultivation of E. coli strains

Media were autoclaved in a 10 L autoclave at 121°C and 1.5 bar for 20 min. For preparation of the
agar plates, the agar was added to the medium before autoclaving. The plates were stored at 4°C
for up to two months.

The incubation of the agar plates was performed at 37 °C in an incubator. The liquid cultures were
incubated at 37°C and 250 r/m in an air shaker. Erlenmeyer flasks or test tubes were used as
containers, which were filled maximal to 10% to ensure an adequate aeration of the culture
medium.

Media

LB medium:
  10 g  Tryptone peptone
  5 g  Yeast extract
  10 g  NaCl
    Final volume to 1000 ml with H2O
                 pH 7.2 with NaOH
   15 g Agar (for plates only)

Antibiotics and IPTG

The solution of antibiotics and IPTG were filtered sterile through a 0.45 µm filter and added to the
pre-autoclaved medium at a temperature under 50 °C.
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                               Table 3.1   Supplements

Supplement Stock solution  Concentration in the medium
Ampicillin 100 mg/ml in H2Obidest  100 µg/ml in liquid cultures
70 µg/ml in solid media
Kanamycin 100 mg/ml in H2Obidest  80 µg/ml in liquid or solid media
Chloramphenicol 50 mg/ml in 50% EtOH 50 µg/ml in liquid or solid media
IPTG 1 M in H2Obidest  1 mM in liquid culture

3.2.2   Storage of E. coli  cultures

The agar plates with E. coli  cultures or the liquid cultures could be stored for a short period of time
(for plates up to two weeks or for liquid cultures up to two days) at 4 °C in a refrigerated room. For
storage of longer periods of time, the cultures were stored in 40% glycerol at - 80 °C, where they
should survive for 1-2 years.

Preparation of glycerol cultures

Sterile tubes (2 ml, with a screw cap) were filled with 500 µl of 80% glycerol and autoclaved. The
same volume of overnight culture grown in LB media was added to the sterile tubes, the tubes
were mixed and stored at – 80 °C.

For the cultivation from single colony, a small portion of the top of the deep-frozen glycerol
culture was streaked on agar plates with a sterile stick. During inoculation the thawing of the
glycerol cultures should be avoided to ensure as long a survival of the cells as possible.

3.3   General methods

3.3.1   Preparation of competent E. coli cells

To achieve a high transformation efficiency the competent cells were prepared according to the
protocol in the handbook. With the cells more than 107  transformants per µg of added DNA can be
obtained depending on the plasmid or the E. coli  strains [10].
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10 ml LB medium were inoculated with a single colony of a bacterial strain and incubated in the
shaker at 37°C and 250 r/m overnight. 250 ml of LB medium with 2 ml of fresh overnight culture
were incubated with rigorous shaking (250 r/m) at 37°C until the cells had reached OD600  about
0.5. Finally the cells were cooled down on an ice bath for 30 min. In order to achieve high
competence of the cells, it is important that the cells should reach the exponential growth phase.

The next steps were carried out in a refrigerated room and pre-cooled solutions as well as
equipment were used. The liquid culture was transferred to two cold 250 ml centrifuge tubes and
centrifuged at 5000 r/m at 2°C for 5 min. The supernatant was discarded. The cell pellets were
carefully resuspended in 25 ml of 0.1 M CaCl2  cold solution and incubated on an ice bath for 30
min. The suspension was precipitated by recentrifugation as above and the supernatant was
discarded. After resuspending the pellets in 10 ml of 0.1 M CaCl2  solution, they were incubated on
an ice bath for 2 h. The cell suspension was divided in 100-200 µl aliquots (containing 15%
glycerol) in cold microcentrifuge tubes and frozen quickly. The competent cells were stored at
-80°C. A transformation with a known amount of plasmid DNA was performed to check the
competence of the cells.

3.3.2   Transformation of competent E. coli  cells with plasmid DNA 

An aliquot of competent cells was thawed in an ice bath. If it was necessary to divide the cells into
smaller aliquots, cooled pipette tips and cold microcentrifuge tubes were used. The volume of the
required cell suspension was dependent on the volume and the concentration of the DNA solution
which was used in the transformation.

After the addition of the DNA solution to the competent cells, the solution was carefully mixed
with a pipette tip. The mixture was incubated on an ice bath for 1 h and afterwards for heat shock
at 42°C for 90 sec. After cooling on ice for 2-5 min, 0.8 ml of LB medium without antibiotics was
added and incubated at 37°C and 200 r/m for 45 min. Depending on the expected transformation
efficiency, 100-150 µl of the cell culture was spread on the agar plates which contained the
appropriate antibiotics. To check the viability of the competent cells, 100 µl of competent cells
were spread on LB plates without antibiotics [10].
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3.3.3   Plasmid minipreparation

3.3.3.1 Alkaline lysis method

Solution I: 50 mM
10 mM
25 mM
Glucose
EDTA
Tris-HCl, pH 8.0
Solution II: 0.2 M
1 %
NaOH
SDS
 Prepare freshly from stock solution
immediately before use.
Solution III: 3 M
5 M
Potassium acetate
Glacial acetic acid
 Mix 60 ml of 5 M potassium acetat, 11.5
ml glacial acetic acid and 38.5 ml water.

1.5 ml of an overnight culture was transferred to a microcentrifuge tube and centrifuged with
13,000 r/m in a table centrifuge for 30 sec. The medium was totally removed with a pipette. The
pellet was suspended in 100 µl of solution I and incubated at room temperature for 5 min.
Afterwards 200 µl of solution II was added and the mixture was shaken by inverting the tube
rapidly but carefully six to eight times and incubated on ice for 5 min. The solution was neutralized
and the dodecyl sulfate precipitated as potassium salt by the addition of 150 µl of solution III. The
mixture was vortexed for 10 sec. Afterwards the tubes were incubated on ice for 5 min. During
centrifugation with 13,000 r/m for 5 min a cell pellet which consists of cell fragments, potassium
dodecyl sulfate and attached proteins or chromosomal DNA was formed.

The supernatant which consists of plasmid DNA and RNA was transferred to a new
microcentrifuge tube and mixed with an equal volume of phenol/chloroform/isoamyl alcohol. After
2 min of centrifugation at 8,000 r/m, the upper aqueous phase was transferred to a new tube. The
plasmid DNA and RNA was precipitated by adding two volumes of 99% ethanol and incubating at
4°C for at least 30 min. After centrifugation at 13,000 r/m for 15 min the supernatant was removed
and the pellet was washed by adding 1 ml of 70% ethanol. The pellet was briefly vortexed and
centrifuged again at 13,000 r/m for 5 min. The supernatant was removed and the pellet was dried
in an desiccator for at least 20 min. The DNA was suspended in 20 µl 10 mM Tris-Cl (pH8.0) that
contained 20 µl/ml RNase and stored at -20°C [10].
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3.3.3.2   Plasmid minipreparation with QIAprepTM Spin Miniprep Kit

The QIAprepTM  Spin Miniprep Kit was used if DNA of high purity was necessary. 2-10 ml of LB
medium with a proper antibiotic addition was inoculated with a single colony and incubated at
37°C and 300 r/m for 10-12 h. 2-5 ml of the overnight culture was divided in 2.5 ml
microcentrifuge tubes and centrifuged at 13,000 r/m for 1 min. The media were removed and the
pellets were resuspended in 250 µl of resuspension buffer P1 until no cell clumps were visible. 250
µl of lysis buffer P2 was added and the tubes was inverted 4-6 times to mix. After addition of 350
µl of neutralization buffer N3, the mixture was inverted and centrifuged at 13,000 r/m for 10 min.
The supernatants were applied from the tube to a QIAprepTM  spin column placed in a 2 ml
collection tube. The columns were centrifuged at 13,000 r/m for 1 min and the flow-through was
discarded. Each column was washed by adding 0.75 ml of washing buffer PE and centrifuging for
1 min at 13,000 r/m. The flow-through was discarded again and the residual washing buffer was
removed by centrifuging as before. The spin column was placed in a fresh 1.5 ml microcentrifuge
tube and 50 µl of elution buffer EB (10 mM Tris, pH7.5) was added to the center of the column.
After 1 min, the tube was centrifuged as before. The plasmid preparations were stored at –20°C.

3.3.4   Purification of PCR products

The PCR product was run on a 1% agarose gel. The gel slice containing the target gene was cut and
melted at 70 oC in a water bath. 1 ml of resin was then added and mixed for 20 sec, after that the
mixture was transferred into a syringe barrel connected to a Wizard Mini-column. The column was
washed one time with 80% iso-propanol, followed by centrifugation at 10,000 r/m for 2 min to
completely remove residual iso-propanol. The Mini-column was then transferred to a new 1.5 ml
Eppendorf tube, and 50 µl of TE buffer was added. The eluted DNA was collected by
centrifugation after 1 min incubation.

3.3.5   Ligation

Ligation were carried out with the T4  DNA ligase only. This enzyme is able to ligate both “stick”
and “blunt ends”. The ligations were carried out in a total volume of 20   l for sticky ends and 50   l
for blunt ends. For blunt end ligation, the solution contained 0.5 mM ATP, 5mM MgCl2  and at least
50 U ligase/ml. For sticky end ligations the supplied ligation buffer was used. The ligation were
carried out at 16˚C overnight.
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3.3.6   Agarose gel electrophoresis

Agarose gel electrophoresis was used for electrophoretic separation, identification and isolation of
nucleic acids. The separation is based on the different electrophoretic mobility of the DNA
molecules. This mobility is dependent on the size and conformation of the molecules. The DNA
fragments in the gel become visible through UV fluorescence of the intercalative agent ethidium
bromide [10].

A DNA marker was used as a reference for the determination of the size of linear DNA fragments.
The DNA /HindIII was cleaved to the bands of 23130, 9416, 6557, 4361, 2322, 2027, 564, 125
bp in agarose gel electrophoresis. For the determination of small DNA fragments, pBR322/BstNI
or X174/HaeIII was used as the marker. The cleaved fragments are from 1857 bp-100 bp or so.
0.9–1% agarose gels are mainly used to separate 0.2-9 kb fragments. To determine smaller
fragments (from 50 bp up), 3-4% agarose gels were used.

For all gels TAE-buffer was used as the electrophoretic solution. For isolating a DNA fragment, the
band was cut out as precisely as possible with a scalpel. It was made sure that the DNA was
exposed to UV light as short as possible to prevent any mutations.
Electrophoresis buffer

 TAE buffer:     0.04 M   Tris-acetic acid
               0.001 M   EDTA
            pH 8.3 with acetic acid

 Loading buffer:  0.25 % Bromophenol blue
              40%    Sucrose


Preparation of the gel and electrophoresis

An adequate amount of agarose in 40 ml TAE buffer was heated in a microwave oven until a clear
solution formed. After cooling the solution down to 50-60°C, 2 µl of ethidum bromide stock
solution (10 mg/ml) was added. The mixture was poured on a gel tray, which had been sealed with
tape. The gel comb was placed in position in the gel. After the gel had solidified (approximately 30
min), the comb was gently removed and the gel was transferred to the electrophoresis chamber
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which was filled with TAE buffer. If necessary, the gel was stored in TAE buffer in 2 days. After
loading the gel, the electrophoresis was carried out at 80 V (40-50 mA) for 90-120 min.

3.3.7   Estimation of DNA concentration

The DNA solutions were scanned in the range 230-330 nm and the concentration was estimated
according to the following relation:
1 OD260  = 33 µg/ml ssDNA
1 OD260  = 50 µg/ml dsDNA

3.3.8   Determination of protein concentration

Protein concentration was determined by the methods of Lowry [11] or Bradford [12]  using bovine
serum albumin as a standard.

3.3.9   SDS-PAGE gel electrophoresis

SDS-PAGE is one of the most powerful and convenient methods for examining macromolecules.
Acrylamide and bis-acrylamide polymerize to form a sieving matrix, which serves to separate
macromolecules by size with polyacrylamide gel electrophoresis (PAGE). The polymerization of
acrylamide forms long chains which are cross-linked together by the addition of the bis-acrylamide.
The pore size of the matrix is inversely related to the total concentration of acrylamide and
bis-acrylamide in solution and the percent of the total monomer which is the cross-linker. SDS is a
strong protein denaturing agent, it can cause proteins to assume a rodlike shape. SDS-treated
proteins have identical charge to mass ratios and similar shapes. The molecular separation is based
on gel filtration and therefore, the electrophoretic mobility of the molecules will be achieved.
[10].

Gel preparation and electrophoresis

First, it is necessary to select the appropriate acrylamide percentage on the basis of the size of
proteins to be separated. The gel apparatus was assembled following the instruction. The gel and
gel buffer were prepared as described in table 3.2 and 3.3. The resolving gel mixture was poured
into the assembled gel plate, leaving sufficient space at the top for the stacking gel to be added
later. The gel was gently overlaid with 200-400   l H2O and polymerised for 30 min or so. After
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polymerisation, the overlay was removed. The stacking gel component was filled into the
remaining space in the gel apparatus with the gel solution and the comb was inserted immediately.
After the upper gel has polymerised, the comb was removed. The wells were rinsed with water to
remove unpolymerized acrylaminde. The gel reservoirs were filled with running buffer. Now
samples were loaded on the gel and it was run usually with constant 18 mA or so. When the blue
dye was at the bottom of the gel, it was stopped. The protein bands can be detected after staining
with CBB and destaining with solvent.

Electrophoresis buffer

Table 3.2   Stacking gel buffer

Components  2 ml 4 ml
H2Obidest 1.4 2.7
30% Acrylamide-bis 0.33 0.67
1.0 M Tris (pH6.8) 0.25 0.5
10% SDS 0.02 0.04
10% Ammonium persulfate 0.02 0.04
TEMED 0.002 0.004

Table 3.3   12% Separating gel

Components  5 ml 10 ml 15 ml
H2Obidest 1.9 4.0 5.9
30% Acrylaminde-bis 1.7 3.3 5.0
1.0 M Tris (pH6.8) 1.3 2.5 3.8
10% SDS 0.05 0.1 0.15
10% Ammonium persulfate 0.05 0.1 0.15
TEMED 0.002 0.004 0.006

Tank buffer:     25 mM   Tris
250 mM  Glycine
0.1%     SDS
pH8.3
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Staining solution:                          Destaining solution:
0.25 g  Coomassie blue R-250                   450 ml  Methanol 
100 ml  Destaining solution                     450 ml  H2Obidest  
                      Acetic acid 10 ml

Sample treatment

To prepare the sample for electrophoresis, the protein solution was mixed with 5X sample loading
buffer according to the ratio of 1:5 in an Eppendorf tube. The tube was put in boiling water for 1-3
min, then cooled down to room temperature. A standard protein marker was used as a reference for
the determination of the size of proteins.

5X sample loading buffer:  250 mM  Tris-HCl, pH6.8
25%      (  -ME)
10%      SDS
0.05%     Bromophenol blue
50%      Glycerol
Store at –20˚C

3.4   Clone of pGEM-hNT3

3.4.1   Preparation of human genomic DNA

The mixture of 50   l human whole blood containing anticoagulant and 0.5 ml TE was centrifuged
at 13,000 r/m for 10 sec. The supernatant was discarded and the precipitate was washed with 0.5
ml TE. After centrifugation, the precipitate resuspended in K+  buffer (50 mM KCl; 10 mM
Tris-HCl; 7.5 mM MgCl; 0.5% Tween 20; 100   g/ml proteinase K) was incubated at 56˚C for 45
min to digest the cells, then incubated at 95˚C for 10 min to inactivate proteinase K.

3.4.2   Amplification of hNT3 gene

To amplify the hNT3 gene from the template of human genomic DNA, 10 µl of 10 x Taq buffer, 8
µl of primer FW (10   M see 2.2.1.2), 8 µl of primer RV (10   M, see 2.2.1.2), 5 µl dNTPs (4 mM
each), 10 µl of MgSO4  (25 mM), 5 µl template of human genomic DNA, 54 µl H2Obidest and 1 µl
Taq were mixed (Table 3.4). The PCR was carried out with the following temperature profile:
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Table  3.4      The  PCR  reaction  system 
 
Materials  Volume  (  l  ) 
10  x  PCR  Buffer  10 
Genome  DNA    5 
dNTP  (4mM)  5 
Primer  (FW)  8 
Primer  (RV)  8 
MgSO4   (25  mM)  10 
dd  H2O    53 
Taq  DNA  polymerase  1 
Total  volume.  100 
 
 
3.4.3      Construction  of  pGEM-hNT3 
 
The  conditions  for  the  ligation  reaction  are  listed  in  Table  3.5.  The  reaction  mixture  was  then 
transformed  into  E.  coli   DH  5α  by  a  heat  shock  procedure  and  plated  on  LB  agar  medium  plates 
supplemented  with  ampicillin  and  Xgal  for  white/blue  screening.  After  incubation  at  37  oC 
overnight,  a  number  of  white  single  colonies  were  picked  and  grown  in  LB  (ampicillin)  medium. 
The  recombinant  plasmids  were  extracted  from  the  cells  as  described  in  Part  III  (3.3.3)  and  the 
insertion  of  hNT3  gene  was  confirmed  as  described  in  Table  3.6. 
 
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 
Table  3.5      Ligation  reaction  system 
 
Materim    Materials  St.  reaction  Posi.reaction  Control 
T4  DNA  Ligase  10  x  buffer 
pGEM-T  Vector  (50  ng) 
PCR  product 
Control  Insert  DNA 
T4  DNA  Ligase  (3  Weiss  unit/µl) 
Add  H2Obidest  to  final  volume 
2    l 
1    l 
15    l 
- 
1    l 
20    l 
1    l 
1    l 
- 
1    l 
1    l 
20    l 
1    l 
1    l 
- 
- 
1    l 
20    l 
*  The  reaction  mixture  was  incubated  at  16ºC  water  bath  overnight 
 
Table  3.6      Enzyme  reaction  system  for  double  cleavage  by  NdeI/SalI 
 
Reactants  Double  cleavage  Single  cleavage 
Plasmid  5    l  5    l 
10  x  SalI  buffer        2    l  2    l 
NdeI                1    l  - 
SalI  1    l  1    l 
dd  H2O        11    l  12    l 
Total    20    l  20    l 
 
 
3.5      Determination  of  biological  activity  
 
3.5.1      hNT3  bio-activity  assay  [13] 
 
3.5.1.1      Collection  of  ganglia 
 
Fertilized  white  leghorn  chicken  eggs  are  put  on  storage  at  10˚C  after  delivery  from  the  supplier 
under  refrigerated  conditions;  the  period  of  the  cold  storage  should  not  be  extended  beyond  3-4 
days.  Eggs  are  transferred  into  an  egg  incubator  at  38˚C  and  rotated  every  day.  After  8  days  of 
incubation,  eggs  are  taken  out  and  the  embryos  are  removed  to  a  frosted  glass  slide  under  a 
dissecting  microscope.  The  embryo  is  rinsed  with  sterilized  1640  medium,  positioned  on  its  back 
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with  outstretched  limbs,  and  opened  up  to  expose  the  ventral  aspect  of  the  spine  with  its  bilateral 
arrays  of  dorsal  root  ganglia  (DRG’s).  Roots  and  nerve  emerging  from  the  ganglia  are  cut  and  the 
individual  ganglia  are  collected  at  room  temperature  into  a  small  plate  with  1640  medium. 
 
3.5.1.2      The  preparation  of  sample 
 
Sample     
 
In  general,  the  sample  was  diluted  with  PBS  buffer  in  a  series  of  concentrations.  The  procedure 
was  continued  to  dilute  the  content  of  each  tube  one  after  one  until  the  desired  dilution  range  was 
achieved.  This  resulted  in  a  series  of  dilution  factors  of  1  (original  sample),  3×10-1,  10-1,  3×10-2, 
10-2,  etc.  A  more  fine  value  of  the  sample  activity  may  require  a  more  precise  dilution  technique 
and  narrow  dilution  intervals  (twofold  or  less)  around  the  previously  established  activity  level. 
This  could  make  the  result  more  reliable. 
 
Preparation  of  collagen  from  rat  tail     
 
The  tail  from  a  rat  about  the  weight  of  250  g  was  taken  out  and  put  into  75%  ethanol  for  30  min. 
After  that,  the  skin  and  muscle  were  removed.  The  tendons  were  cut  into  small  pieces  and 
dissolved  by  150  ml  0.1%  HAc  by  shaking  gently,  at  4°C  for  48  h.  The  extraction  solution  was 
centrifuged  at  4000  r/m,  30  min.  The  supernatant  was  divided  into  10  ml  portion,  put  into  small 
bottles  and  stored  at  -20°C.     
 
3.5.1.3      The  assay 
 
In  general,  the  following  procedure  is  convenient:  A  series  of  sterile  culture  bottles  (20×10×5  mm) 
were  streaked  out  with  collagen  of  rat  tail.  3  ml  DMEM  was  added  into  a  bottle  and  incubated  in 
CO2-incubator  overnight.  Next  day,  the  individual  ganglia  collected  at  room  temperature  under  a 
dissecting  micro-scope  was  given  into  this  culture  bottle,  usually  two  ganglia  per  bottle,  and  mixed 
with  500    l  of  diluted  sample.  The  patterns  of  fiber  outgrowth  elicited  from  the  explanted  ganglia 
by  the  different  gradient  of  sample  concentration  are  examined  by  phase  contrast  microscopy  at  a 
magnification  in  24  h.  One  biological  unit  of  the  sample  is  defined  as  having  the  same  outgrowth 
response  as  1  biological  unit  of  sample  of  nerver  growth  factor  (15  ng)  [16].  All  of  steps  described 
above  were  performed  under  sterile  condition. 
 
Materials  and  Methods         
 
-   102  -
3.5.2      ELISA   
 
ELISA  provides  a  sensitive  and  quantitative  detection  of  special  antigens  or  antibodies.  Wells  of 
microtiter  plates  were  coated  with  2    g  protein  in  100    l  coating  buffer  and  incubated  at  4˚C 
overnight.  The  coated  plates  were  washed  3  times  with  200    l  PBST  at  room  temperature.  After 
washing,  the  wells  were  saturated  with  200    l  of  1%  BSA  in  PBS  for  1.5  h  at  room  temperature 
and  washed  with  PBST  three  times.  The  first  antibody  diluted  in  PBS  was  added  to  each  well  and 
incubated  for  2  h  at  room  temperature  (100    l/per  well).  Afterwards,  each  well  was  washed  with 
PBST  three  times  before  adding  100    l  of  secondary  antibody  diluted  with  PBST  for  1  h  at  room 
temperature.  The  wells  were  continuously  washed  with  PBST  four  times  respectively.  The  first 
antibody  bound  was  measured  by  peroxidase  activity  with  P-nitrophenyl  phosphate  as  the  substrate. 
The  color  developed  about  30  min  was  measured  at  405  nm  using  a  microtiter  plate  reader  [14]. 
 
Solution 
 
Coating  buffer:                                                        PBS  buffer: 
A:  0.2M 
 
Na2CO3                                                                              2.5  mM      Na2HPO4       
B:  0.2M
   
NaHCO3                                                                               2  mM        NaH2PO4         
Make  up  fresh:  17  ml  A+8  ml  B                                0.14  M      NaCl       
pH10.6                                                                        pH7.2 
Final  volume  to  100  ml                                              Final  volume  to1000  ml 
 
PBST:  100  ml  PBS+0.45  ml  Tween  20 
 
Block  solution:  1%  BSA  in  PBS  buffer 
 
Substrate  buffer:                                        Substrate: 
0.2  g    NaN3                                                 10  mg  P-nitrophenyl  phoshate  +10  ml  Substrate  buffer 
0.1  g    MgCl2.6H2O     
97  ml    DEA                 
pH9.8 
Final  volume  to1000  ml 
 
 
 
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3.5.3      Western  blots  
 
Western  blot  analysis  involves  in  gel  electrophoresis  the  presence  of  SDS  which  results  in 
denaturation  and  separation  of  molecules  on  the  basis  of  size.  These  molecules  are  then  transferred 
to  another  matrix  to  form  a  pattern  on  the  matrix  identical  to  that  on  the  gel.  In  general,  antigens 
immobilized  (blotted)  on  a  membrane  from  SDS-PAGE  are  detected  with  primary  antibodies.  The 
appropriate  enzyme  conjugated  with  the  secondary  antibody  results  in  the  deposition  of  colour 
substrate  on  the  membrane  at  the  reaction  site.  This  colour  provides  a  visual  indication  of  potential 
primary  antibody  recognition. 
 
Western  blots  were  made  by  electrophoresis  transfer  of  proteins  from  SDS-PAGE  into 
nitrocellulose  membrane  by  sandwich  electrophoresis.  After  transfer,  the  membrane  was  incubated 
in  1%  milk  powder  (free  lipid)  in  TBST  for  1  h  to  saturate  nonspecific  protein  binding  sites.  The 
membrane  was  washed  with  TBS  three  times.  To  bind  primary  antibody,  the  blocking  solution  was 
replaced  with  TBST  containing  the  appropriate  dilution  of  primary  antibody  and  incubated  for  2  h 
with  gentle  agitation.  In  order  to  remove  unbound  antibody,  the  membrane  was  washed  three  times 
with  TBS  for  10-15  min.  Finally,  the  membrane  was  incubated  in  TBST  containing  the  appropriate 
dilution  of  anti-Ig  AP  conjugate  for  1  h  with  gentle  agitation.  The  membrane  was  washed  four 
times  to  remove  the  unbound  secondary  antibody  in  TBS  and  reacted  with  BCIP/NBT  substrate 
until  the  color  of  the  target  protein  occurred  and  re-transferred  into  PBS  to  be  fixed  immediately. 
This  procedure  was  done  at  RT  [15]. 
 
Solutions 
 
TBS:                                                                                            AP  buffer: 
10  mM      Tris-HCl,  pH8.0                                                        100  mM    Tris-HCl,  pH9.5 
150  mM    NaCl                                                                          100  mM      NaCl 
TBST:                                                                                          5  mM        MgCl                   
TBS+0.05%  Tween  20     
 
AP  color  development  solution: 
10  ml  AP  buffer 
66    l  NBT 
33    l  BCIP 
 
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3.5.4      The  inhibition  of  protein  synthesis  in  vitro  
 
The  rabbit  reticulocyte  lysate  translation  system  plays  an  important  role  in  the  identification  of  the 
investigation  of  transcriptional  and  translational  regulation.  The  procedure  was  performed  on  96 
wells  of  microtiter  plates.  To  examine  the  toxicity  of  the  fusion  protein,  a  series  of  samples  were 
diluted  as  follows  3.16x10-8  M,  3.16×10-9  M,  3.16×10-10  M,  3.16×10-11  M,  3.16×10-12  M  to 
3.16x10-13  M.  5    l  solution  taken  out  from  each  diluted  sample  was  added  into  a  well  of  the  test 
plate  and  mixed  with  40    l  complement  lysate,  37ºC  incubator  for  5  min.  Then  10    l  master 
mixture  containing  L-(U-14C)-valine,  50    Ci  was  added  into  each  well,  incubator  10  min  again. 
After  that,  two  parallel  5    l  culture  from  each  well  were  added  into  1  ml  pre-cool  double  distilled 
water,  mixed  with  500    l  valine  (1mg/ml)  at  37ºC  for  15  min  (each  sample  should  be  repeated). 
Finally,  the  protein  precipitated  by  4  ml  25%  TCA  (two  times)  was  dried  on  glass  microfiber  filters 
with  vacuum.  The  microfiber  was  incubated  with  5  ml  of  radioactivity  solution  of  β-counter 
(Beckman  LS1701)  for  2  h  at  RT.  It  was  then  assayed  for  the  radioactivity  [16]. 
 
Solution  A:                                                                      Solution  B: 
250    l      H2Obidest                                                                                          242  mg      Tris 
250    l      Glycerol                                                            373  mg      KCl 
2.5  mg      Creatinkinase                                                    90  ml        Ethylene  glycol 
                                                                                          10  ml          H2Obidest  
                                                                                          pH8.2 
                                                                                          65.2  mg      Hemin 
 
Solution  C:                                                                      Solution  D: 
6.7  mg    Creatinphosphate                                              9.5  mg    MgCl.6H2O 
100    l    H2Obidest                                                                                          1.45  g      KCl 
                                                                                        10  ml      H2Obidest 
Solution  E:  L-(U-14C)  valine  (50    Ci/ml=1.85  MBq/ml)  was  purchased  from  Amersham 
 
Solution  F:    Amino  acids  solution 
7.5  mM:          alanine;  leucine 
5  mM:            aspartate;  glutamate;  glycine;  histidine;  lysine;  serine 
3.75  mM:        arginine;  asparagine;  glutamine;  isoleucine;  phenylalanine;  proline;   
                        threonine;  thryptophan;  tyrosine 
2.5  mM:          cysteine;  methionine 
Materials  and  Methods         
 
-   105  -
 
Complement  Lysate:                                              Master  Mix: 
970    l    Lysate  (Promega)                                      50    l    Solution  C 
10    l      Solution  A                                                50    l      Solution  D 
20      l      Solution  B                                                80    l      Solution  E 
20    l      Solution  F 
Valine  solution:       
1  M          NaOH 
0.5  M        H2O2  
100  mg    Valine 
Final  volume  to  100  ml 
 
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Abbreviations  
 
 
AID  Acquired  immune  deficiency 
AchR  Nicotinic  acetylcholine  receptor 
Ach  acetylcholine 
ATP  Adenosine-5’-triphosphate 
Amp  Ampicillin 
BCIP  5-bromo-4-chloro-3-indolyl  phosphate 
BDNF  Brain-derived  neurotrophic  factor 
bp  Base  pairs 
BSA  Bovine  serum  albumin 
CBB  Coomassie  brilliant  blue   
CBD  Chitin  binding  domain 
cccDNA  Cycle  close  covalent  DNA 
cDNAs  Complement  DNA 
Chl  Chloramphenicol 
CIAP  Calf  intestine  alkaline  phosphatase 
CNTF  Ciliary  neurotrophic  factor 
CySH  Cysteine 
DEA  Diethanolamine 
DNA  Deoxyribonucleic  acid 
dNTP  Deoxyribonucleoside-5’-triphosphate 
dsDNA  Double  strand  DNA 
DTT  1,4-dithiothreitol 
EAMG  Experimental  autoimmune  Myasthenia  gravis 
E.  coli   Escherichia  coli  
EDTA  Ethylendiamin-N,N,N’,N’-tetraacetic  acid 
ELISA  Enzyme-linked  immuno  sorbent  assays 
EtBr  Ethidium  bromide 
EtOH  Ethanol 
FGF  Fibroblast  growth  factors 
FPLC  Fast  performance  liquid  chromatography 
GSH    Glutathione 
GSSG  Oxidized  glutathione 
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GST  Glutathione  S-  transferase 
GuHCl  Guanidine  hydrochloride 
HAc  Acetic  acid 
hNT3  Human  Neurotrophins  3 
HIV  Human  immunodeficiency  virus 
IPTG  Isopropyl--thiogalactopyranoside 
KAc  Potassium  acetate 
Kan  Kanamycin 
Kb  Kilo  bases 
KD  Kilo  dalton 
KDEL  lysine-aspartate-glutamate-leucine 
LM  Low  melt 
MAb  Monoclonal  antibody   
MG  Myasthenia  gravis 
MIR  Main  immunogenic  region 
Mops  3-(N-morpholino)-1-propane  sulfonic  acid 
MW  Molecular  weight 
 
-ME  β-Mercaptoethanol 
OD  Optical  density 
RIPs  Ribosome  inactivating  proteins 
scRIPs  Single  chain  ribosome  inactivating  proteins 
dsRIPs  Double  chain  ribosome  inactivating  proteins 
NBT  Nitroblue  tetrazolium 
NGF  Nerve  growth  factor 
NT-3  and  NT4/5  Neurotrophins  3,  4/5 
P/C/I  Phenol/chloroform/isoamylalcohol 
PCR  Polymerase  chain  reaction 
pI  Isoelectric  point 
PMSF  Phenylmethyl  sulfonyl  fluoride 
RNase  Ribonuclease 
r/m  (rpm)  Rounds  per  minute 
rRNA  Ribosomal  ribonucleic  acid 
SCID  Severe  combined  immunodeficiency 
SDS  Sodium  dodecylsulfate 
SDS-PAGE  SDS-Polyacrylamide  gel  electrophoresis 
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ssDNA  Single  strand  DNA 
TE    Tris-EDTA 
TEMED  Tetramethylethylenediamine 
Tris  Tris(hydroxymethyl)-aminomethane 
Trk  molecules  Tyrosine  receptor  kinases 
UV  Ultraviolet 
X-gal  5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
   
 
 
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